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The use of automated or semi-automated approaches based on imaging data has been suggested 
to support the diagnoses of some diseases. In this context, Machine Learning (ML) appears as a 
useful emerging tool for this purpose, allowing from feature extraction to automatic classification. 
Alzheimer Disease (AD) and Frontotemporal Dementia (FTD) are two common and prevalent forms 
of early-onset dementia with different, but partly overlapping, symptoms and brain patterns of 
atrophy. Because of the similarities, there is a need to establish an accurate diagnosis and to obtain 
good markers for prognosis. This work combines both supervised and unsupervised ML algorithms 
to classify AD and FTD. 
The data used consisted of gray matter volumes and cortical thicknesses (CTh) extracted from 3T-
T1 MRI of 44 healthy controls (HC, age: 57.8±5.4 years), 53 Early-Onset Alzheimer Disease 
patients (EOAD, age: 59.4±4.4 years) and 64 FTD patients (FTD, age: 64.4±8.8 years). A 
principal component analysis (PCA) of all volumes and thicknesses was performed and a number 
of principal components (PC) that accumulated at least 80% of the data variance were entered into 
a Support Vector Machine (SVM). Overall performance was assessed using a 5-fold cross-
validation. 
The algorithm proposed achieved an accuracy of 91.7±5.76 % in the HC vs EOAD classification, 
83.3±5.2 % for HC vs FTD, 83.0±5.8 % for EOAD vs FTD and 77.7±5.2 % when performing a 
multiclass classification between the 3 groups. The first PC was used to create disease-specific 
patterns. 
By using a low number of features, combining information from CTh and subcortical volumes, the 
algorithm proposed is able to classify HC, EOAD and FTD with fairly good accuracy. Thus, this 
approach can be used to reduce the amount of data used in ML algorithms while providing 
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1.1. Alzheimer Disease and its diagnosis 
The National Institute of Aging (NIA) defines Alzheimer’s Disease (AD) as an irreversible, 
progressive brain disorder that slowly destroys memory and thinking skills, and, eventually, the 
ability to carry out simple daily tasks, until patient’s death [1]. AD affects people over the age of 65, 
but early-onset AD (EOAD) is also diagnosed in patients younger than 65. The brain of an 
Alzheimer patient accumulates abnormal proteins (Aβ and tau) in the form of amyloid plaques and 
neurofibrillary tangles [2], eventually resulting in an irreversible loss of neurons. Currently, AD is 
the most common neurodegenerative disease, representing the principal cause of dementia in the 
elderly population of developed countries. In 2020, over 50 million people worldwide suffered 
dementia, and these numbers are expected to reach the 152 million cases in 2050 due to population 
aging [3]. 
Although AD has no cure, there are medicines available that help in delaying the disease progress. 
Thus, its early diagnosis is essential.  
In 2011, the National Institutes of Health (NIH) and the Alzheimer’s Association developed an 
updated diagnostic guidelines with respect to the previous one, published in 1984. In this 
guidelines, three stages of AD were described: a preclinical stage, characterized by the first brain 
changes, including amyloid build-up, without significant clinical symptoms evident; a Mild Cognitive 
Impairment (MCI) stage, attributed to a loss of cognitive functions regarding memory, but that do 
not interfere with the patient’s independence; and Alzheimer’s dementia, to which some of the MCI 
patients evolve, marked by a progressive impairment in memory, decision making, orientation and 
language, significant enough to affect a person’s daily life [4]. 
According to the same guidelines, in preclinical stages, the amyloid build-up can be found with 
positron emission tomography (PET) imaging and a cerebrospinal fluid (CSF) analysis, however, 
the future prognosis is still unknown. In a more advanced stage, in MCI, the research for diagnosis 
is focused on standardizing biomarkers for amyloid plaques and other signs of injury to the brain. 
Among these biomarkers, elevated levels of tau or decreased levels of beta-amyloid in the CSF 
are found, as well as reduced glucose uptake in the brain observed in PET scans. Also, atrophy of 
certain brain areas detected by high-resolution structural Magnetic Resonance Imaging (MRI) 
is well-correlated with both tau deposition and neuropsychological effects, so it becomes another 
biomarker of AD and its progression. Finally, the diagnosis criteria for Alzheimer’s dementia, which 
applies to the last stage of the disease, includes biomarkers testing to increase the sureness of the 
diagnosis and to distinguish Alzheimer from other types of dementias. [5,6] 
As stated above, the intensity and stage of the neurodegeneration can be identified with the help 
of atrophy measurement of certain brain areas with structural MRI (sMRI), such as the 
hippocampus, the entorhinal cortex or the amygdala. Therefore, sMRI-based feature extraction 
happens to play an important role in AD diagnosis and prognosis [7]. The objective of feature 
extraction is to retrieve a set of accurate quantified features such as size, shape or volume, from 
neuroimaging data that contain relevant information for the disease diagnosis. 
Nonetheless, manual measurements of these structures on MRI are time-consuming and do not 
capture the full pattern of atrophy [8]. Therefore, many automated and semi-automatic feature 
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extraction techniques exist for high-resolution sMRI data analysis, which consist of several image-
processing and statistical analysis steps. [9]. 
When applying feature extraction methods, neuroimaging modalities generate an extreme huge 
amount of data. Thus, to analyse it and observe inherent patterns in the data, there is a need for 
multivariate data analysis and Artificial Intelligence (AI) techniques, such as Machine Learning (ML) 
[10].  
1.2. Artificial Intelligence: machine learning 
In 2019, the High-Level Expert Group on Artificial Intelligence (HLEG) defined AI systems as 
“software (and possibly also hardware) systems designed by humans that, given a complex goal, 
act in the physical or digital dimensions by perceiving their environment through data acquisition, 
interpreting the collected structured or unstructured data, reasoning on the knowledge, or 
processing the information, derived from this data and deciding the best action(s) to take to achieve 
the given goals.” These systems can use symbolic rules or learn a numeric model [11]. Also, AI 
encompasses many techniques, such as Machine Learning (ML); machine reasoning, which refers 
to scheduling, search and optimization; and robotics, which includes sensors and actuators [12]. 
Machine Learning is a subfield of AI which consists of building models or applications that learn 
from data, called training data, in order to improve its accuracy when predicting the outcome of new 
data without being explicitly programmed to do so. There are different ways in which ML algorithms 
learn from the training data: 
Supervised learning. In this type of learning, expert humans feed the algorithm with labelled data, 
that is, pairs of inputs with known outputs. Then, the algorithm looks for the function which best 
maps the input data to the output in a generalizable from. Supervised learning is useful in either 
classification or regression problems. In classification problems, the algorithm predicts a discrete 
value for the input data, identifying each data point with a specific class. On the other hand, 
regression problems work with continuous numeric data. 
Unsupervised learning. Sometimes, well-labelled data sets are not easy to obtain. In these cases, 
algorithms learn completely by themselves by finding unknown patterns in the data without any 
labels. Unsupervised learning aims to find structure in the data by extracting useful features and 
analyzing them. The way the model organizes data is different depending on the problem. One of 
the ways is clustering, where the model looks for training data with similar features and groups 
them together in what is called a cluster. Another common way is association, in which the model 
looks for some key attributes in a data point and predicts the other ones by checking them in those 
data points with which the point is correlated [13].  
Semi-supervised learning. These are hybrid algorithms lying between supervised and 
unsupervised models. The training dataset is filled with both labelled and unlabelled data, which is 
a common situation in those cases where labelling data requires from expert human skills. 
Reinforced learning. This kind of learning is common in robotics, since it allows machines to 
determine in an automatic way the best behaviour in a specific context which maximizes the model 




1.3. Machine Learning and neurodegenerative diseases diagnosis with sMRI 
As mentioned, clinical studies have demonstrated that measures of structural atrophy using sMRI 
data are a promising biomarker for an accurate diagnosis of AD patients. Thus, automatic 
volumetric measures of cortical and subcortical volumes, together with measures of cortical 
thicknesses (CTh), both extracted from sMRI images, happen to be essential biomarkers for early 
detection of the AD [14].  In addition to providing certainty to the diagnosis of the disease, its non-
invasive nature and the consequent lack of pain for the patient, make structural MRI a comfortable 
and effective diagnostic test. 
Nevertheless, the utility of these sMRI-derived data is not limited to differentiate controls from 
affected patients, but is also useful in differentiating AD from other clinical pathologies, such as 
frontotemporal dementia (FTD), which, together with AD, is one of the leading causes of early-
onset dementia. However, FTD differs from Alzheimer in the sense that FTD patients usually 
develop early noncognitive behavioural changes together with frontal atrophy in sMRI scans, while 
AD patients have early cognitive changes and relatively reserved behaviour together with 
hippocampal, entorhinal cortex and medial-temporal lobe atrophy on sMRI scans [15]. 
Moreover, brain tissue loss from the whole brain or specific regions, as well as the rate of structural 
atrophy measures, highly correlates with cognitive deficits changes [16], so they are also great 
biomarkers for the diseases progression.  
Recent advances in neuroimage and its analysis have led to new useful automated tools to extract 
valuable neuroimaging information. These techniques generate large datasets encompassing 
whole brain regions instead of single regions of interest (ROI), which must be manually segmented 
and rely on previous knowledge. Then, if all the measurements extracted from the MRI scans aim 
to be useful for AD diagnosis, this triggers the need for automatic classification methods that 
perform equally or even better than experts in the high-consuming clinical task of recognising 
patterns in the data for further diagnosis. Furthermore, the fact that those methods are able to use 
whole brain information makes them more capable of distinguishing between healthy, AD patients 
and other types of neurodegenerations, since a single region, like the temporal lobe, can be also 
damaged in other types of diseases.  
For this purpose, many automatic classification algorithms have already been implemented, 
providing useful tools when analyzing the data and finding inherent disease-related patterns in it. 
The models used include from Support Vector Machines (SVM) to K Nearest neighbours (KNN) or 
Decision Trees, all of them supervised learning algorithms. Many other studies as [17] also use 
neural networks. 
Nonetheless, feature extraction directly from sMRI leads to very high dimensional data. Thus, when 
dealing with such large datasets, a reduction of data dimensionality is usually needed, particularly 
when the number of labelled subjects is small. Some ways of achieving this goal are discarding 
some of the features extracted and keeping others or projecting the data to a reduced dimensional 
space with some dimensionality reduction techniques such as Principal Component Analysis 
(PCA). 
It is worth mentioning that the application of these algorithms is not limited to subject classification 
between controls, EOAD or other neurodegenerative diseases such as FTD, but they are also a 
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great tool to study which brain regions are more atrophied in each disease and, therefore, more 
significant for the posterior classification. Thus, when a model is applied, it is not only its 
interpretability that matters, understanding interpretability as the ability of the algorithm to determine 
a cause and its effect, such as an atrophied region and the consequent disease, respectively. 
Instead, attention should also be paid to explainability, which can be defined as understanding 
which factors from the data are causing the differentiation between subjects from different groups 
and what is the reason. 
1.4. Objectives  
All the previous concepts comprise the needed context to appropriately follow the presented 
project, which main goal is to research on an automatic machine learning classification tool for 
early-onset Alzheimer Disease diagnosis. The model aims to predict if a patient is either healthy, 
suffering from EOAD or suffering from FTD, thus helping doctors in the disease diagnosis and 
differentiation from other neurodegenerative diseases. All of this, by taking as inputs the cortical 
and subcortical volumes, together with the CTh measurements extracted from the patient’s 
structural MRI scan. 
Furthermore, some secondary objectives for the project were defined: 
➢ Conduct an in-depth research on the state of the art of automated classification 
systems applied to MRI extracted data that provide certainty in the diagnosis of Alzheimer 
Disease. Thus, reviewing the different algorithms employed and the results obtained, 
taking into account the data being used. 
 
➢ To implement a pipeline able to classify between patients and healthy controls 
including a dimensionality reduction step and a classification algorithm, which must be 
chosen considering the performance obtained but also the computational cost and the 
capability of the models to be generalized. 
 
➢ Explore which brain regions appear more atrophied in AD or, in other words, which 
regions result more significant for the classification and subsequent diagnosis, and check 
if they match with the ones reviewed in the literature. 
 
➢ To add patients suffering from frontotemporal dementia to the original dataset in order to 
perform a multiclass classification pipeline. Therefore, a second automated classification 
tool capable of distinguishing between three groups (controls, EOAD patients and 
FTD patents) aims to be developed. 
 
➢ Finally, to assess if there are actual differences in the brain atrophy pattern between 
AD and FTD and, if positive, to explore the significant regions differentiating both 
neurodegenerative diseases. 
1.5. Spatial and temporal limitations of the project  
The main limitations of the project were temporal and due to the global pandemic situation. 
Firstly, the thesis was developed in a relatively tight time window, from February to June 2021. This 
fact, in addition to cause a more intensive work and less spaced, limiting the realization of any 
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changes or correction to the framework, restricted even more the time available for obtaining 
controls and patients samples. Furthermore, the data with which the work was developed comes 
from neurologists of the hospital, which had to stop their usual activities during the pandemic to be 
dedicated full time to Covid19. This fact, added to the temporal limitation, presented an extra 
limitation to the size of the sample used to train the algorithm. 
However, it was not only a sample’s size limitation which was encountered, but also problems with 
other neuroimaging modalities data availability, such as DTI, which could have added certainty to 
the classification and led to better performances. 
Finally, mobility and capacity restrictions supposed that all the meetings of the team were online, 
adding an extra difficulty in communication and organization. 
1.6. Scope of the project 
As stated before, the main objective of the project is to perform a pipeline able to classify EOAD 
patients from healthy subjects. Furthermore, a third group with FTD dementia patients aims to be 
added and classified. 
In order to meet this goal, the scope of the project encompasses: delving into the machine learning 
world and its applications related to sMRI neuroimaging for the diagnosis of neurodegenerative 
diseases; the development of an automated pipeline for further classification between controls, 
EOAD and FTD patients, including a dimensionality reduction step, a classification step and a 
performance assessment. In addition, to obtain clinical information useful for research, the retrieval 
of the disease-related patterns of both EOAD and FTD, therefore analysing which features or brain 
regions contribute with the highest variance to the data. 
On the other hand, the T1-weighted scans pre-processing, as well as the extraction of the CTh and 
the cortical and subcortical volumes from the images is out of the scope of the project. Also, the 
addition of other biomarkers of AD and FTD, such as PET-fluorodeoxyglucose (PET-FDG) scans 
or CSF analysis, or other MRI modalities like DTI, is also non contemplated. Finally, since this 
project has purely research objectives and needs further investigation, the algorithm is not intended 




2. STATE OF THE ART 
In the last few years, many multivariate data analysis tools and machine learning algorithms were 
used in the field of neurodegenerative diseases, and particularly of Alzheimer Disease, since it is 
the most common one. Assuming that AD is correlated with progressive changes in brain structure 
and functionality, significant results have outcome from the implementation of automated softwares 
capable of finding patterns in the data extracted from sMRI that lead to a high accuracy diagnosis 
of the disease. 
2.1. Search criteria 
Since wide range of different cohorts, features and methods were used in numerous studies, a set 
of different papers regarding ML application in AD research centred on sMRI were reviewed, as 
well as classification pipelines proposed for distinguishing AD patients from FTD ones. However, 
many similar ML approaches for classifying MCI patients likely to convert to AD (cMCI) from those 
non-converters (ncMCI) were published, so the different algorithms and methods implemented in 
this classification task have also been reviewed. 
The search was done in PubMed, looking for articles in English published from 2008 up to March 
2021 using the search term “Alzheimer Disease” combined with “Machine Learning”, 
“Frontotemporal Dementia”, “structural MRI”, “SVM”, “Decision Trees”, “KNN”, “PCA” and “MRI 
data”. To include an article in the state-of-the-art review, it was checked that both T1-weighted 
sMRI data and a ML algorithm were used. 
Usually, a classification framework includes feature extraction, a feature selection or dimensionality 
reduction step, a classification algorithm to develop a robust predictive model and a validation 
method to validate the performance (Figure 1). Therefore, the diverse methods employed in each 
step in the studies were pointed out. Nevertheless, as mentioned in the previous section, feature 
extraction is out of the scope of the project, so little research was made of this subject.  
 
Figure 1: main steps of a conventional neuroimaging classification pipeline. 1) Cross-validation, 2) feature extraction, 3) 
dimensionality reduction, 4) classification and 5) performance evaluation. 
Followingly, a summary table (Table 1) with most of the articles reviewed is presented, showing 
the different steps beforementioned:
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Article Type of classification Number of 
observations 






Performance evaluation (best 
results) 
[20] Binary: AD-HC, FTD-HC AD-
FTD 
37 AD, 12 FTD, 49 
age-matched HC 
sMRI: GM and WM VBM PCA SVM 10-iterations 
LOO CV 
Accuracy:  AD-HC 99.7%, AD-FDT 
84.3%, FTD-HC 100% 
[21] Binary: AD-HC, FTD-HC AD-
FTD 
84 AD, 51 FTD, 94 
HC 
sMRI: GM-VM, WM-VBM, CSF  None SVM Holdout 
method 
Accuracy: AD-HC 88% FTD-HC 
85%, AD-FTD 82%. 
[25] Binary: EOAD-HC, EOFTD-
HC EOAD-EOFTD 
24 EOAD, 33 EOFTD, 
34 HC 
sMRI: WM-VBM, GM-VBM, CSF, 
DTI: FA 
None SVM 4-fold CV AUC: EOFTD-EOAD 84% (sMRI + 
FA), 72% (sMRI). 
[18] Binary: AD-HC, HC-cMCI, 
cMCI-ncMCI 
144 AD, 189 HC, 136 
cMCI, 166 cnMCI 




SVM 20-fold CV AUC: AD-HC 97%, HC-cMCI 92%, 
75% cMCI- ncMCI. 
[24] Binary: AD-HC, HC-cMCI, 
cMCI-ncMCI 
81 AD, 171 HC, 39 
cMCI, 35 ncMCI 
sMRI: CSC thicknesses, 
hippocampal volume, and VBM 




AUC: AD-HC 94%, HC-cMCI 95%, 
cMCI- ncMCI 87%. 
[19] Binary: HC-AD. Multiclass: 
HC-AD-MCI 
70 HC, 70 AD, 74 
MCI 
CSC thicknesses, subcortical 
volumes 
PCA SVM and RELM 10-fold CV Accuracy: HC-AD 80%, HC-AD-
MCI 61.5% 
[28] Binary: HC-AD, cMCI- ncMCI 226 HC, 182 AD, 389 
(cMCI+ ncMCI). 
VBM and CSC thicknesses RFE SVM 10-fold CV Accuracy: AD-HC 90%, cMCI- 
ncMCI 72%. 
[22] Binary: AD-HC, HC-MCI, 
cMCI-ncMCI 
117 AD, 122 MCI, 112 
HC 
Subcortical volumes and 
hippocampal volume 
None Orthogonal Partial 
Least Squares  
7-fold CV Accuracy: AD-HC 89%, HC-MCI 
84%, CMCI/ ncMCI 68% 
[26] Binary: AD-HC, HC-MCI 51 AD, 99 MCI, 52 
HC 
93 GM-ROI from MRI, 93 ROI from 
PET and 3 features from CSF 
t-test SVM 10-fold CV Accuracy: AD-HC 93.2% HC-MCI 
76.4% 
[29] Binary: HC vs FTD Multiclass: 
HC vs FTD subtypes 
96 FTD, 84 HC sMRI: CSC GM, subcortical 
volumes and total WM DTI: FA 
PCA KNN, SVM, RF, 
LR and LDA 
10-fold CV Accuracy: 88% HC-FTD, 76% HC-
FTD subtypes 
[31] Multiclass: AD-FTD-HC 34 AD, 30 FTD, 14 
HC 
sMRI: CSC GM, subcortical 
volumes and total WM 
PCA SVM LOO CV AUC: 76.5% HC-AD-FTD 
Table 1: state of the art resume table. Reviewed studies for AD classification pipelines and the methods used in each step: groups being classified, nº of observations, feature extraction method, dimensionality 
reduction algorithm, classification algorithm, validation method and performance evaluation and results. GM: gray matter, WM: white matter.
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2.2. Feature extraction 
In machine learning, features are a subset of variables that are given as input data to the classifiers, 
so they aim to quantify accurate information from neuroimaging data able to cover the most relevant 
patterns of the neurodegenerative disease. Since it is an important step in the classification 
framework and can directly affect its performance, many automated and semi-automated methods 
were implemented for analyzing sMRI images. 
The features extracted by the different methods range from a single voxel to cortical and subcortical 
substructures, or even whole brain data. However, for neuroimage classification purposes, the most 
common measurements are cortical or subcortical volumes and CTh [18,19], while voxel-based 
morphometry (VBM) [20,21] is mostly used for structural comparisons between subjects.  
Also, methods based on single regions are used, in particular segmentations of the hippocampus 
[22] and the entorhinal cortex, which appear in the literature as atrophied regions in AD. 
Nonetheless, adding more regional and global measures of the brain to the hippocampal volume 
has proven better performances [23]. Finally, other studies combine as well different sets of 
features that have shown to improve the performance, such as VBM and cortical and subcortical 
(CSC) measures [24], also including features from other neuroimaging modalities, such as DTI [25], 
or PET-FDG [26]. 
2.3. Feature selection 
As stated in the introduction, feature extraction methods tend to generate huge amounts of data, 
leading to the so-called curse of dimensionality, which consists of computational difficulties when 
dealing with high dimensional data and a small number of subjects. In such circumstances, the 
classification tends to overfit the data, which makes the algorithm non-generalizable. Therefore, to 
overcome this problem, a reduction of the data dimensionality is needed, with the aim to reduce 
the number of features that are given as inputs to the classifier. In [27], it was demonstrated that 
choosing the appropriate feature selection or dimensionality reduction method has a positive effect 
in the resulting accuracies of the classification, so many approaches were implemented in different 
studies. 
The main methods used for feature selection in the literature can be divided between unsupervised, 
which do not see the class labels and choose those features that maximize data variance, and 
supervised. Among the unsupervised methods, the most common approach implemented in many 
studies classifying AD patients from HC or DFT patients, was principal component analysis 
[20,22,24], which consists of transforming the data into a subspace of lower dimensionality that 
explains most of the data variance. 
On the other hand, supervised methods can be classified between filter, wrapper and embedded 
methods. The first ones, which are independent from the classifier being used and select relevant 
features regarding general traits of the data, are used by means of a t-test in [26] to select the most 
discriminative brain regions. Wrapper methods, on the contrary, consider the classifier being used 
and aim to find the feature subset that maximizes its performance. Among these methods, 
Recursive Feature Elimination (RFE), which eliminates a specified number of features at each 
iteration, was used in [28] to classify AD patients from controls and cMCI from ncMCI. Finally, 
embedded methods, such as random forests used in [18] for feature selection, combine filter and 
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wrapper methods properties. It is implemented by classification algorithms which already have their 
own feature selection methods built-in or, in other words, that perform feature selection in their 
training. 
2.4. Classification algorithms 
A wide range of supervised classification algorithms were implemented in the field of AD diagnosis, 
as well as in classification works that aim to distinguish between AD and other diseases such as 
FTD. As mentioned, these kinds of classifiers used data labels to learn from a training set for further 
prediction of unknown samples. 
The most common algorithm used in the neurodegenerative field for binary classifications were 
Support Vector Machines [20,21,18,19]. In short, this algorithm consists of finding a hyperplane in 
the feature space that best separates the datapoints belonging to different classes. Then, new 
datapoints are mapped into the feature space and predicted as one class or another depending on 
which side of the hyperplane they fit.  
Although SVM is the most used classifier, other algorithms are reported in the literature. In [24], the 
K-Nearest-Neighbours (KNN) classifier was compared to SVM for classifying MCI types and AD 
from controls and proved to not perform as good as SVM. KNN classifier assumes that datapoints 
belonging to a same group are mapped closed to each other in the feature space. Therefore, as in 
SVM, the algorithm maps the different datapoints and stores their labels, but in this case, when the 
test samples are mapped as well in the feature space, they are labelled as the most common class 
in their k-nearest training points. 
Other studies such as [29] have implemented an embedded algorithm such as Random Forests 
(RF) or Decision Trees for both feature selection and classification tasks. These are supervised 
classifiers that follow a flowchart-like structure composed by nodes, branches and leafs. Each node 
is labelled with an input feature and the branches coming out from that node are labelled each of 
the possible values that the feature can take. Then, these branches lead either to another internal 
node labelled with a different feature or to a leaf, a terminal node that will be labelled with a class 
or a probability distribution of the classes. When choosing which feature performs the best split at 
a given node, the certainty in a particular prediction aims to be maximized. 
Logistic Regression (LR) and Linear Discriminant Analysis (LDA) performances, both supervised 
algorithms, were also assessed in [29]. In binary classification problems, LR uses a logistic function 
to output a linear equation result between 0 and 1, which corresponds to the probability of belonging 
to a class or another. On the other hand, LDA projects the data onto a one-dimensional straight 
line, such that the data points belonging to a same class are as close as possible. 
When performing multiclass classifications between AD, FTD and HC, some research groups have 
used deep neural networks [30]. However, machine learning algorithms such as SVM have also 
showed good results [31]. 
Finally, each of the mentioned classifiers depends on a series of parameters, which can be 
optimized for a given training set with a cross validation method, such as in [25] or [24]. 




2.5. Validation method 
The main idea of model validation is to use a part of the data set to fit and train the classifier and 
another part to test and evaluate it. 
Among the different methods, the holdout method, the k-fold cross-validation (CV) and the Leave 
One Out (LOO) CV are examples. The holdout method consists of randomly splitting the dataset 
into a train and a test sets, the first one used for the learning step and the second one to evaluate 
the performance. In [21], the holdout method was used to evaluate the classification accuracy 
between AD and FTD patients. On the other hand, k-fold CV is one of the most common 
approaches, and consists of dividing the subject’s sample into k-folds and using each of the folds 
as a test set in different iterations while the other folds remain as training set. It was used in [18,28] 
to classify AD from HC and MCI converters from non-converters. Finally, LOO cross validation was 
used in [20] to evaluate the performance of the classification between AD and FTD patients. It 
consists of taking k-fold CV to the extreme, since k happens to be equal to the number of samples 
in the data set, leaving a single subject aside for testing at each iteration. 
In [19], Kumar R. et al. compare the three cross-validation methods that have just been explained 
in both a binary and a multiclass classification frameworks. The results show that in the binary 
classification the performance was better with LOO CV and in the multiclass classification the 
outcomes were better with 10-fold CV. 
2.6. Performance evaluation 
It is not a simple task to compare the performances of the methods obtained in the different studies 
by just looking at the results presented. The reason to this, in addition to the fact that each study 
uses its own feature extraction and selection method and classifier, is that the performances of the 
pipelines are assessed with different metrics. 
The most common way of evaluating performance along the different studies was accuracy, which 
is defined as the number of correct predictions divided by the total number of predictions. Also, 
other metrics such as Cohen’s kappa value were used to evaluate the model performance [24], 
which, unlike accuracy, takes into account the imbalance in class distribution. It is defined as the 
overall accuracy of the model minus the probability of agreement between the model predictions 
and the real class values if randomly predicted, all of this divided by 1 minus the same agreement. 
Other studies like [25] evaluate the performance of the classifier with the Area Under the Curve 
(AUC), which measures the two-dimensional area under the ROC curve, which is a curve defined 
by the true positive and the true negative values. 
2.7. Studies that reported significant regions in AD and FTD 
Finally, some of the papers reviewed have reported a list of brain regions found to be significant 
and discriminative when classifying AD patients from controls, FTD patients from controls and AD 
patients from FTD.  
In [20], many areas from the temporal and frontal lobes (e.g., orbitofrontal cortex), as well as the 
parietal lobes and medial structures appeared to be discriminative for AD-FTD classification. Also, 
in [25], the results confirm the temporal lobe contribution to the AD-FTD distinction, but also specify 
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the middle frontal gyrus and periventricular regions as discriminative. In [31], the discriminative 
power of hippocampus and ventricles was assessed and showed greater ventricular differences 
between the two groups: AD and FTD. 
On the other hand, brain regions that were reported as significant for AD-HC classification are 
temporal lobe and periventricular regions, as well as the hippocampus and the amygdalas [31]. In 
FTD-HC classification, the temporal lobe is the one with grater discriminative power, but also 




3. MARKET ANALYSIS   
3.1. Addressed sector  
As stated in the introduction, the classification pipeline implemented was mainly addressed to 
Alzheimer patients. According to Alzheimer Disease International (ADI), almost 10 million people 
worldwide develop dementia every year, from which around 5 million cases are AD. The incidence 
rates observed in early 2000s for younger adults (below the age of 60) were of 2.4 cases per 
100,000 people per year, whereas this rate increased to 127 cases per 100,000 people per year 
for the population over 60. After 65, the incidence of the disease exponentially increases with age. 
Thus, the main target sector are subjects over 65 suspected of suffering dementia caused by AD. 
The prevalence of AD is on the rise, mainly attributed to the increasing diagnostic rates and 
awareness of the disease [32]. The conventional methods for diagnosing AD, as can be cognitive 
ability tests such as Mini Mental State Examination (MMSE), or biopsies, fail the 50% of the time, 
mainly due to a lack of consensus on AD biomarkers. Thus, the need for effective and well-
orchestrated diagnostic tools for the disease gives place for brain imaging. 
3.2. MRI versus other neuroimaging techniques for AD diagnosis 
Brain imaging is a recent diagnostic improvement method thanks to the progressive advancements 
in technologies and proved correlations in structural, functional and molecular findings to the 
disease onset and progression. Since there are no definitive guidelines for a diagnosis of AD, the 
most popular approach is to exclude other possible diagnosis, narrowing the possibilities to a 
probable AD case. Actually, brain imaging facilitates this exclusionary process by providing 
structural imaging of the brain and its regions, also enabling the differentiation of AD from other 
similar pathologies as FTD or vascular dementia. With the findings of biomarkers linked with the 
disease in clinical trials, brain imaging techniques are increasingly being used for safety monitoring. 
In Table 2 [32], some of the most used brain imaging technologies in the AD diagnosis context and 
their main advantages and disadvantages are summarized. Although PET brain imaging allows for 
an accurate early diagnosis of AD, its price and invasive nature limits the technique, since 
radioactive substances must be injected in the patient’s body. Also, PET becomes less useful when 
monitoring the disease progression and later stages of AD. In these aspects, MRI emerges as a 
great advantage since it is really sensitive to structural brain changes of the disease, allowing for a 
progressive disease monitoring. Moreover, MRI is completely non-invasive. 
Technique Application Advantages Disadvantages Average 
Price (€) 
CT Structural Quick, easy and widely available. Low resolution and limited 
use. Not sensitive to 
structural changes. 
348.70 
MRI Structural Widely available, high-resolution 
and safe. Sensitive to structural 
changes. 
Low, lacks molecular 
specificity. 
2137.22 
SPECT Functional Detects brain changes through 
disease progression, low-cost 
alternative to PET. 
Less specific and sensitive 
tool than PET. Low spatial 




PET Molecular Good for early detection of AD. 
Applied for monitoring Aβ loads in 
the brain via tracer molecules. 
Limited availability. 
Radioactive chemicals 
injected into body.  
5484.25 
Table 2: comparision between different neuroimaging techniques that can be applied for AD diagnosis. Computed Tomography 
(CT), strucural MRI, Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) are 
compared. [32] 
3.3. Historical evolution of the market 
Once brain imaging started to become a key biomarker in AD diagnosis and other 
neurodegenerative diseases, in the mid-90’s, statistical mapping and voxel-based analysis of the 
brain began to gain prominence in the neuroimaging field. The use of these methods was first 
limited to explore anatomical or functional differences between groups or to investigate correlations 
between imaging and cognitive symptoms. However, group comparisons usually do not allow to 
develop individually based imaging scores, which is essential to establish diagnosis indices for a 
single subject [33]. 
Because of this, in the early 2000’s, the application of machine learning methods to neuroimaging 
studies aroused a lot of interest. This enabled the development of imaging signatures of brain 
structure that could be detected in single subjects. The earlier studies published on this topic were 
focused on SVM algorithms, which are an actual key aspect in neuroimaging diagnosis because of 
its ease of use and robustness. Another family of methods that gained popularity around 2001-
2002 were random forests since they became very generalizable algorithms. Deep learning was 
the latest incorporation in the field and allowed to learn complex features in a hierarchical way. 
In the last few years, the applications of machine and deep learning in neuroimaging studies were 
numerous, not just for AD but also for schizophrenia, Parkinson, and other diseases. However, this 
is a field that, until now, has been mainly limited to research studies and centres. 
In Figure 2, the publications in PubMed from 2004 until 2020 found by searching MRI and Machine 
Learning are presented. As can be seen, the number of publications has increased exponentially 
in the last few years. 
 
Figure 2: number of publications found in PubMed by year with the keywords “structural MRI” AND “Machine Learning” AND “AD” 
from 2004 to 2020. 
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3.4. Future perspectives 
In light of the above, with an increasingly aging population, Alzheimer’s cases are expected to 
increase up to 75 million in 2030. And, although until now the field of AI applied to the diagnosis of 
AD has been quite limited to the research framework, it is expected that in the years to come new 
branches of large companies including this type of diagnosis will appear. In addition, new start-ups 
will be founded, such as the already existing qmenta [34] or qubiotec [35]. These enterprises offer 
powerful clouds for clinical trials, research and clinical care, where the clients can upload their 
neuroimages and they have them back together with a probability assigned to a determined 
diagnosis. 
Moreover, new innovation centres focused on health technology, born from hospitals together with 
other technological entities, are also expected to increase in number. An actual example of this is 
the Clinical Advanced Technologies Innovation (CATI), a new centre promoted by Hospital Clínic 
and the technological centre Leitat. In this public-private collaboration, many enterprises have 
shown their interest in being part of it, some of them including AI solutions towards a personalized 
medicine. 
Finally, it is worth mentioning that in the specific AD context these emerging AI algorithms not only 
provide diagnostic support but also become a key tool to assess the efficacy of treatments for the 
disease. An example is aducanumab, a monoclonal antibody which was recently commercialized 




4. CONCEPTION ENGINEERING 
Once the contextualization and the background of the project were reviewed, in this section, the 
different software options and algorithms for dimensionality reduction, classification and validation 
that can be implemented to address the previously defined objectives, will be discussed. 
4.1. Analysis of the solutions 
Below, a summary table with the different options raised regarding the programming software, the 
dimensionality reduction and classification algorithms, and the cross-validation method. 
 
Table 3: Conception engineering. Studied solutions for the programming software, dimensionality reduction algorithm, classification 
algorithm, and validation method. 
4.1.1. Programming software 
The proposed model could be implemented with different programming languages: Python [36], R 
studio [37] or MATLAB [38] among others. 
Python is a free simple programming language which stands out for its easy to learn syntax. 
However, despite its fast interpretability, it is a high-level object-oriented and interpreted language. 
It supports many modules and packages, among which there is Scikit-learn or Sklearn, a widely 
used library for ML applications. Sklearn [39] is built on NumPy, SciPy and matplotlib, and supports 
classification, regression, clustering, dimensionality reduction, model selection and pre-processing 
tools. 
MATLAB is a private system of numeric computing that uses its own programming language called 
“M language”. It is also a user-friendly environment, mainly used for matrices manipulation, data 
and functions representation and algorithms implementation. It has its own range of packages, 
including a Statistics and Machine Learning Toolbox [40] which applications are remarkably similar 
to those in Sklearn: descriptive statistics, clustering, multidimensional data analysis and feature 
extraction, supervised classification, etc. 
Finally, R studio is a free integrated development environment that uses R programming language 
for statistical computation and graphical representations. R, together with Python, is one of the 
more powerful tools for ML programming. It supports many ML packages such as CARET for 









• Unsupervised: PCA 
• Supervised 
- Wrapper methods: RFE / FFS / BFS 
- Filter methods 
 
Classification algorithms 
• K-Nearest Neighbours 
• Support Vector Machine 
• Decision Trees 
 
Validation method 
• Leave One Out CV 
• K-fold CV 
• Holdout method 
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classification and regression problems, random forest or e1071 for SVM and Naive Bayes 
classifiers, etc.  
4.1.2. Dimensionality reduction 
Principal Component Analysis is an unsupervised learning algorithm that transforms the original 
dataset into a subspace of lower dimensionality while capturing its maximum variability. This is 
done by finding a few new variables, directions uncorrelated with each other, that successively 
maximize variance and that are linear combinations of the features in the original set. These 
directions are the so-called Principal Components (PC) [41]. The result is a first PC being the 
direction along which the samples show the greatest variance, the second PC the direction, 
uncorrelated to the first PC, that shows the second greatest variance, and so on. The main uses of 
PCA are descriptive since it does not require any distributional assumptions regarding the dataset.   
On the other hand, the most relevant supervised methods include Linear Discriminant Analysis and 
feature selection algorithms such as wrapper and filter methods. 
LDA is a dimensionality reduction technique which, similarly to PCA, aims to project the dataset 
into a lower dimensionality subspace. However, LDA is supervised, so it creates the new subspace 
while maintaining the class-discriminatory information, finding linear combinations of the original 
features that maximize the separation between multiple classes. 
 
Figure 3: PCA (left) and LDA (right) graphical differentiation. PCA seeks for the directions in the dataset that capture the maximum 
data variability, while LDA aims to maximize the separation between groups. [42] 
Wrapper methods include a classifier into the feature selection algorithm and search for a feature 
subset that maximizes its performance. Wrapper methods are usually classified into Sequential 
Selection and Recursive Feature Elimination (RFE).  
Sequential selection begins with an empty subset and first looks for the feature that maximizes the 
objective function, which in this case is the algorithm performance. Then, searches for another 
feature in the whole dataset that, added to the first one, also maximizes the performance. And 
keeps adding features in that way until the specified number of selected features is reached. The 
feature selection technique just described is the Forward Feature Selection (FFS) algorithm. If, 
on the contrary, the algorithm starts with a full subset and keeps eliminating the feature that causes 
the least performance loss at each iteration, it is called Backwards Feature Selection (BFS).  
On the other hand, in order to find the best performing subset, recursive feature elimination 
eliminates n features from the total number (m), leaving the desired number of features (m-n), 
specified at the beginning. This is performed by fitting the given ML model multiple times and, at 
each iteration, ranking features by importance and discarding the weakest ones. 
17 
 
On the contrary, filter methods are independent of the classification algorithm and performance. 
They look for significant features by means of an information entropy test or other statistical 
dependencies. Starting with a feature subset (randomly selected or empty), they first evaluate the 
subset with the corresponding test and check if the result for the previous best subset was better 
than the actual one. If true, it is set as the current best feature subset. This process is continued 
until a certain criterion is met, which can be either the fact that the addition or removal of a new 
feature does not achieve better results or that a predefined performance threshold is achieved [43].  
4.1.3. Classification algorithm 
Support Vector Machine is a supervised machine learning algorithm that can be used both for 
classification and regression analysis, although it is more commonly employed for classification. 
This algorithm aims to find an optimal hyperplane of M -1 dimensions in an M-dimensional space 
(M: number of features) that best separates the different classes of data points from a training data 
set. The data points with the minimum distance to the hyperplane are called support vectors and, 
this minimum distance, also called margin, is maximized to find the optimal hyperplane. Then, new 
examples or cases are mapped to the M-dimensional space and predicted to belong to a class or 
another based on which side of the hyperplane they are mapped.  
K nearest neighbours is also a supervised machine learning classifier algorithm that works under 
the assumption that similar datapoints are close to each other in the M-dimensional feature space. 
In the training phase, KNN maps the different feature vectors and stores the class labels of the 
training examples. Afterwards, each of the unlabelled data points are classified by assigning them 
the most common label among the k training points nearest to them. The distance d from the tested 
point to its k nearest train points can be assessed using different metrics, being the Euclidean or 
the Hamming distances two of the more common [44].  
A Decision Tree is a supervised embedded algorithm that can be used both for regression and 
classification problems. It has a flowchart-like structure composed by nodes, branches and leafs. 
Each node is labelled with an input feature, and the branches coming out from a node are labelled 
with each of the possible values that the feature can take. These branches lead either to another 
internal node or to a leaf, a terminal node that will be labelled with a class or a probability distribution 
of the classes. When predicting a class label for a new data observation, the algorithm starts from 
what is called the root of the tree, the beginning node containing the entire dataset, and the different 
paths from the root to the leafs represent classification rules. The growth of these paths involves 
deciding which feature to choose for each node that best splits the set of data, and what conditions 
to use for splitting an internal node in two or more branches [45]. 
4.1.4. Validation method 
As stated in section 2, the holdout method simply consists of splitting the dataset into single train 
and test sets, the first one for teaching the algorithm and the second one to check the algorithm 
performance on unseen data. A common split of hold-out method is to put the 80% of the data into 
the training set and the remaining 20% into the test set.  
On the other hand, cross-validation methods, such as k-fold CV, rely on a resampling procedure. 
Usually, the implementation of these models follows 4 steps. First, the dataset is shuffled randomly, 
secondly it is split into k-groups, thirdly, iteratively each group is used once as a test set while the 
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other groups are forming the training set with which the model being tested will be fitted. Finally, 
the performance of the model is summarized with the mean of the k iterations. Thus, k-fold CV 
makes sure that each fold is only used once for validation. 
Finally, Leave One Out CV is a type of k-fold CV where k happens to be equal to the number of 
samples in the data set, leaving a single subject aside at each iteration. It gives each sample a 
chance of being test by the algorithm. 
Both k-fold and LOO present a clear advantage with respect to the simple holdout method, since 
in small datasets the holdout is highly dependent on the splits produced. This problem is overcome 
with cross-validation. However, the main disadvantage of LOO is its computational cost, since the 
process requires a fitting and validation of the model as many times as the number of samples [46]. 
4.2. Proposed solution 
In accordance with the above-mentioned, the programming environment finally chosen was Python. 
The main reason was that a ML introduction course was done using Sklearn, so the library was 
already familiar. Also, Python offers an open-source software, which allows to open the code in 
other computers without the need of downloading any payment software. However, R studio was 
also implemented to perform a statistical analysis between the demographic data of the different 
subject groups and to plot the diseases patterns onto an atlas. 
The data dimensionality was finally reduced with PCA. The choice was partly made because of 
computational reasons since feature selection algorithms are iterative and therefore much more 
time consuming. Moreover, PCA was applied because it becomes a very powerful tool to obtain 
both conceptual and graphical clinical information about which brain regions are differing more 
between groups. And, also, since it is an unsupervised method, it results a generalizable algorithm 
with a low risk of overfitting despite the number of samples is limited, which lead to choose it over 
LDA. 
In order to choose the number of PCs, the cumulative explained variance was taken as condition. 
An optimal number of PCs is a number which cumulative variance sums at least the 80% of the 
total variance of the dataset. However, if the threshold is set much higher, there is a risk of 
overfitting.  
At the end, the ML classification algorithm used were support vector machines. The main reason 
that led to this choice was that SVM have been reported in the literature to be the ML algorithm that 
leads to better performances [24,29]. Moreover, Decision Trees were discarded because of their 
nature as embedded algorithms. This means that decision trees include (embed) the feature 
selection step into the own algorithm, making it difficult to retrieve the features selected in each 
node and extract the most significant brain regions. Finally, since the dataset used was relatively 
small and SVM is reported to obtain better results than KNN, the last one was also discarded. 
Finally, the validation method implemented was k-fold CV to avoid split dependency. K-fold was 
chosen over LOO because of computational reasons, since LOO performs a number of iterations 
equal to the number of observations N, meaning that the model must be fitted N times. Moreover, 
LOO has a higher risk of overfitting, since the final performance is meaned between N models 
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trained with practically the same data, with the only difference of one observation. In contrast, the 




5. DETAILED ENGINEERING 
As mentioned, the main goal of the project was to develop an automated machine learning pipeline 
able to determine if a new patient who had undergone a structural MRI was suffering from AD or 
FTD, or if he/she was healthy. Also, the aim was to retrieve relevant clinical information about which 
brain regions were differing between the two ill and healthy brains. Therefore, both a binary 
classification study and a multiclass one were performed. The first mentioned aimed to classify 
between pairs of groups (AD patients and HC, FTD patients and HC, and AD patients and FTD 
patients) and study the brain atrophy patterns between the pairs. On the other hand, the multiclass 
study purposed to classify a new patient in one of the three groups. 
To do so, the incoming structural MRI data, segmented with FreeSurfer into cortical thicknesses 
and cortical and subcortical gray matter volumes, was first divided into train and test sets with a k-
fold cross-validation. Then, the dimensionality was reduced with PCA. In this step, the weights 
given from the first PC to each feature were stored and used to determine the most relevant brain 
regions between groups, which were plotted in a brain map. Followingly, the data transformed into 
the PCA subspace entered the classification step, were the SVM algorithm, which parameters were 
cross-validated, was fitted with the train set and then predicted the test set data labels. Finally, the 
performance of the model was assessed with the mean accuracy of the classification and a 
confusion matrix. In Figure 4, the general implemented pipeline is represented. 
 
Figure 4: diagram showing the implemented pipeline. Starts splitting the dataset according to the cross-validation method (1), then 
Principal Component Analysis (PCA) is implemented (2) and the weights of the quantified brain regions are extracted, followed by 
Support Vector Machine (SVM) for the classification step (3). Finally, the performance is assessed (4). Parameter k corresponds to 
the number of iterations. 
5.1. Data management 
The data used in this study comes from the Alzheimer and Memory unit in Hospital Clinic of 
Barcelona. It consists of a subset of 53 EOAD patients and 44 HC and 64 FTD patients, resulting 
in 161 subjects. Each subject was doubly acquired with a 3T Siemens MRI scanner with a T1-
weighted magnetization-prepared 180 degrees radio-frequency pulses and rapid gradient-echo 
(MP RAGE) sequence. For each subject, cortical thicknesses and subcortical GM volumes were 
segmented by the Alzheimer and Memory unit (Agnès Pérez) using FreeSurfer, which is an open 
software for analyzing human brain structural and functional MRI images, used for the study of 
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cortical and subcortical brain anatomy. From this segmentation, a total of 36 cortical thicknesses 
from different structures were obtained for both right and left hemispheres, and also 65 subcortical 
volumes, including both right and left hemisphere measurements. However, the features that 
contained many null values or had a large number of void values were eliminated from the raw 
dataset. In order to work with manageable data, the format was transformed to .csv and read with 
Pandas library in Python.  
Since the scope of this study did not include comparing differences between left or right hemisphere 
regions, we calculated the mean between left and right measures. Also, when comparing volumes 
between different subjects, it is good practice to normalize them for the total intracranial volume 
(TIV) to avoid significant differences that are due to the brain size and not because of the disease. 
Thus, each volume measure was normalized to the TIV and the intracranial volume was dropped 
from the dataset. Finally, a z-score normalization (Equation 1) was applied to the data in order to 
have comparable ranges of values for all features. HCs were labelled with a 0, the EOADs with a 
1 and the FTDs with a 2.     
     𝑧 =
𝑥− 𝑚𝑒𝑎𝑛
𝑠𝑑
  (eq. 1) 
Moreover, demographic data was acquired for each group, containing both age and sex. To check 
if age differences existed between the three groups, an ANOVA test was carried out with R studio. 
On the other hand, sex differences were checked with a Fisher test. Regarding age, the ANOVA 
test showed a p-value of 1.4·10-6 (<0.05), meaning that significant differences in age between the 
three groups existed. In sex, although differences were not that big, a p-value of 0.03 was obtained. 
Thus, a post-hoc study was carried out using t-test to identify the pair-wise differences driving each 
result. The p-values obtained for age were 0.26, 4.4·10-6 and 1.3·10-5 between EOAD and HC, HC 
and FTD, and EOAD and FTD data, respectively. Regarding sex, the p-values were 0.3, 0.03 and 
0.3 for EOAD-HC, FTD-HC and EOAD-FTD respectively. 
Thus, the age and sex variables were included in the multiclass pipeline. In binary studies, age was 
added in all of them except for HC-EOAD, and sex was only added to HC-FTD. At the end, the 
feature space dimension was reduced to 59 for the multiclass and the HC-FTD studies, 58 for 
EAOD-FTD and 57 for HC-EOAD. The header of the EOAD-FTD feature set is shown in Figure 5. 
 
Figure 5: example taken from the data table for HC vs EOAD. Showing only 5 subjects and 7 features from the total. 
5.2. Implemented pipeline 
5.2.1. Cross-validation 
With the data already imported and normalized using z-score, the data was first divided into 
features (X) and labels (y) Then, it was split into train (X_train, y_train), and test (X_test, y_test) 
sets with a stratified 5-fold cross-validation. The fact that the k-fold was stratified allowed that the 
splits, instead of being completely random, had a ratio between the target classes in each fold 
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equal as the one in the full dataset, so the folds are compensated. Also, 5 folds were chosen so 
that in each split approximately the 20% of the data was left for testing, while the resting 80% was 
used for training. In Figure 6, a graphical representation of the stratified 5-fold cross-validation 
implemented in the 3-group classification is shown. 
 
Figure 6: stratified 5-fold cross-validation implemented for the 3 groups. HC, EOAD and FTD subjects. At each iteration, a different 
fold containing the 20% of the dataset is reserved for testing. 
5.2.2. Dimensionality reduction 
Once the data was split into a train and a test sets, and already in the cross-validation loop, the 
feature space dimensionality was reduced using Principal Component Analysis, which was also 
used to retrieve those features apporting more variance from the whole sample of each study.  
As mentioned before, PCA is an unsupervised algorithm that reduces the dimensionality m of a 
dataset of N observations to a subspace of dimensionality p<m. It looks for uncorrelated PCs, which 
are linear combinations of the original features comprising the maximum variability of the data. The 
classic method for finding the PCs is the maximum variance approach [47]. The process starts with 
a N x m matrix, K, with mean-centred columns (kj). The algorithm seeks for the linear combination 
of columns of the matrix with maximum variance, and these linear combinations are given by 
equation 2, where a is an m-dimensional vector of weights a1, a2,...,am. 
∑ 𝑎𝑗𝑘𝑗 = 𝐾𝑎
𝑚
𝑗=1    (Eq. 2) 
Then, the variance of such linear combination is given by equation 3, where C is the covariance 
matrix of K. This will consist of a square matrix of mxm dimensions denoting the covariance of each 
feature with the others (Figure 7). From here, finding the linear combination with maximum variance 
or first principal component (PC1), translates into looking for a vector a that maximizes this equation 
(Eq.3).  
At the end, assuming that a must be unit-norm vectors, what results is the following equality 
(equation 4), where 𝜆 and a end up being the eigenvalues and eigenvectors of C, respectively, 
which come from the diagonalization of the covariance matrix. 




Figure 7: covariance matrix. m x m matrix representing the covariance of each feature with the other features. 
The higher the eigenvalue, the higher variability in that direction, so the algorithm aims to find the 
largest eigenvalue and its corresponding eigenvector. A matrix composed by the eigenvectors can 
be constructed, where each vector or column corresponds to a PC. Then, by arranging them in 
descending order of variability, that is, by their eigenvalues, one acquires a matrix with the first PC 
as the first column, the second PC as the following column etc.  
In Python, the decomposition module of the Sklearn library supports a PCA function in which the 
user can indicate the number of features or PCs to be extracted. In order to calculate the optimal 
number of PCs, in a previous step to the cross-validation, a PCA model was fitted with all the X 
data and set to get all the possible principal components, which equal the original feature space 
minus one: 55 for the EOAD vs HC study 56 for EOAD vs FTD and 57 the rest. From here, the 
explained variance accumulated by each component was calculated and the number of 
components that accumulate the 80% of the variance was assessed. In Figure 8, the cumulative 
variances versus the number of principal components for each group classification is shown.  
 
Figure 8: cumulative variances for all the principal components in each classification study. Minimum number of components 
needed to accumulate the 80% of the data variance is marked with a dashed line. Where “nc” states for number of principal 
components. 
The minimum number of PCs needed to accumulate the 80% of the dataset variance for each study 
was stored in a variable and entered to the cross-validation loop. There, the X_train was used to fit 
PCA, which was set to assess the number of PCs found in the previous step, and both X_train and 
X_test data were transformed into the new subspace. Followingly, the lists of weights given to the 
different features or regions by each component were stored in a dictionary with keys equal to the 
number of PC and values equal to a list of shape (nº iterations, nº features). At the end of the cross-
validation, the mean and standard deviations of the weights given to each feature were calculated. 
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Since the first principal component itself accumulated approximately the 40% of the data variance, 
the weights given by this component to each feature were then stored in a .csv file. The file was 
read in R studio and used to represent the weights of each region graphically in a brain map. 
5.2.3. Classification 
Once with the train and test data transformed into the PCA subspace, the Support Vector Machine 
algorithm was fitted with the train set and used to classify the test data into the different classes. 
As explained, SVM aims to find a hyperplane of m-1 dimensions that best separates the different 
data classes from the training set. When the dataset is linearly separable, two parallel hyperplanes 
are defined such as the distance between them is 
maximized (Figure 9). Then, the optimal 
hyperplane with the maximum margin, is the one 
lying halfway the other two. The equations defining 
the two parallel hyperplanes are (Eq. 5) and (Eq. 6), 
where b is a biased term, WT is the summatory of 
the normal vectors to the hyperplane, and X is the 
the summatory of the data point vectors. Both b and 
W parameters must be found so they maximize the 
margin distance. Then, every point on or above 
boundary Π1 is of a determined class and every 
point on or below boundary Π2 is of another class 
[48]. Therefore, for the classification of every new 
datapoint, the decision function in Eq. 7 is used: 
𝛱1 = 𝑤
𝑇𝑋 − 𝑏 = 1       (𝐸𝑞. 5) 
𝛱2 = 𝑤
𝑇𝑋 − 𝑏 = −1   (𝐸𝑞. 6) 
𝐷(𝑥) = 𝑠𝑔𝑛(𝑤𝑇𝑥 + 𝑏) (𝐸𝑞. 7) 
Sometimes, when data is not linearly separable, a projection of the data to a higher dimension, 
where it can be linearly separated, is needed to avoid outliers. This is what is called the kernel trick. 
In this non-linear classification, every dot product of two vectors in the algorithm is replaced by a 
kernel function, that allows to fit the hyperplane in a transformed feature space. Different kernel 
functions can be used (Figure 10), among others, there exist:  
 
Figure 10. From left to right: graphic exemplification of Support Vector Machine classification with linear, polynomial and RBF 
kernels, from left to right [49]. 
Linear kernel: 𝐾(?⃗?𝑖 , 𝑥𝑗⃗⃗⃗ ⃗) = (?⃗?
𝑇
𝑖 , 𝑥𝑗⃗⃗⃗ ⃗). It is equivalent to use a SVM without the kernel trick. 
Figure 9: SVM classification. Grpahical representation of the 
hyperplanes generated by the algorithm. 
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Polynomial kernel. It is a more generalized linear kernel, since it can classify curved or non-linear 
input spaces. 𝐾(?⃗?𝑖 , 𝑥𝑗⃗⃗⃗ ⃗) = (?⃗?
𝑇
𝑖, 𝑥𝑗⃗⃗⃗ ⃗ + 𝐶)
𝑑
, where C is a constant term and d is the kernel’s degree. 
RBF (Radial Basis Function). The Gaussian Radial Basis function is the most common 
one: 𝐾(?⃗?𝑖 , 𝑐𝑒𝑛𝑡𝑒𝑟) = exp (−𝛾||𝑥𝑖⃗⃗⃗ ⃗ − 𝑐𝑒𝑛𝑡𝑒𝑟||
2
). The γ parameter controls the weight of new training 
points. The higher its value, the more dependent of the closer points the decision boundary will be. 
Therefore, if γ is set too high, there might be risk of overfitting. 
The effectiveness of SVM depends both on the kernel selection and its parameters. As mentioned 
before, when RBF kernel is used, the γ parameter must be chosen. On the other hand, the soft 
margin C parameter dictates the trade-off between maximizing the margin of the decision function 
and minimizing mistakes in the classification of training points [50]. For a smaller C, classification 
mistakes of the training data are given less importance and the algorithm focuses on maximizing 
the margin, while for higher C values, a smaller margin is accepted if the decision function classifies 
better all training points. Hence, when choosing a higher C value, overfitting must be watched out. 
In order to find the optimal kernel and parameters for the SVM classification, the GridSearchCV 
function from the Sklearn model_selection module was implemented. This function takes as main 
inputs an estimator and a parameter grid. It performs an exhaustive combinatory search over the 
parameter’s ranges given, fitting the X_train for each parameter combination and then scoring the 
estimator performance with the train labels y_train. Also, the performance can be cross validated 
any number of iterations by passing an integer number to the cv parameter of the GridSearchCV 
function. In this case, the cv parameter was set to 10. 
The different parameter combinations passed as a grid to the GridSearchCV function consisted on 
three different kernels (linear, polynomial and RBF) combined with a C range of values from 0.1 to 
1000 in logarithmic scale. Also, for the RBF kernel, a γ value was added to the combination, ranging 
from 0.001 to 1 in logarithmic scale. The combinations are shown in Table 3. 
KERNEL C  γ 
LINEAR Range: 0.1, 1, 10, 100, 1000 ------  
POLYNOMIAL Range: 0.1, 1, 10, 100, 1000 ------ 
RBF Range: 0.1, 1, 10, 100, 1000 Range: 0.001, 0.01, 0.1, 1 
Table 4: combination of parameters for the SVM estimator. C and γ values combined with each kernel in the grid search. C: soft 
margin parameter. γ :  specific parameter for the RBF kernel that controls the weight given to new training points.  
Once the GridSearchCV function finds the optimal combination, it builds a classifier with that 
parameters. The resulting SVM estimator was then trained with the X_train and y_train data and 
used to predict the X_test labels, which were stored in a variable called y_pred.  
Finally, the predicted labels were compared with the true labels (y_test) in order to build a confusion 
matrix and to assess the overall accuracy of the prediction and the specific accuracy of each class. 
The overall accuracies were calculated using the accuracy_score function and the specific ones 
with the classification_report function, both provided by the metrics module of Sklearn. Then, once 
outside the cross-validation loop, the mean values of the accuracies and standard deviations were 





The results obtained could be separated in two different categories: a first one regarding the 
achieved algorithm performance and a second one concerning all the clinical information that 
resulted from the exhaustive analysis realised to the implemented algorithm. 
5.3.1. Algorithm performance 
As mentioned, the number of PC to be used in each classification study was assessed with the 
cumulative explained variance. The results were shown in Figure 8. The number of PC used were 
11, 9, 10 and 10 for the HC vs EOAD, HC vs FTD, EOAD vs FTD and the multiclass studies, 
respectively. The classification capability of the pipeline implemented was obtained by assessing 
its performance using the 20% of the data for testing in a 5-fold cross-validation. For each study 
(HC vs EOAD, HC vs FTD, EOAD vs FTD and HC vs EOAD vs FTD), the specific precisions for 
each group of subjects, as well as the overall classification accuracies, were calculated and the 
mean values were obtained across the 5 iterations. In Table 5, the total accuracy of each 
classification study, as well as each group precision, accompanied by the standard deviations, are 
shown. Also, Figure 11 presents the confusion matrices showing the mean of the true-predicted 
and false-predicted values for each study. 
 STUDY 
 HC (Group 1) vs 
EOAD (Group 2) 
HC (Group 1) vs 
FTD (Group 2) 
EOAD (Group 1) 
vs FTD (Group 2) 
HC (group 1) vs EOAD 
(group 2) vs FTD (group 3) 
Mean accuracy 91.7% ± 5.8% 83.3% ± 5.2% 83.0% ± 5.8% 77.7%  ±  5.2% 
Precision group 1 92.8% ± 6.6% 76.0% ± 4.7% 81.79% ±10.5% 70.7%  ±  8.3% 
Precision group 2 91.0% ± 5.9% 89.9% ± 6.6% 86.3% ± 5.8% 80.8%  ±  4.2% 
Precision group 3 ------------------------ ------------------------ ------------------------ 83.3%  ±  10.4% 
Table 5: accuracies mean values (%) and standard deviations (%) obtained for each classification study (HC vs EOAD, HC vs FTD, 
EOAD vs FTD and HC vs EOAD vs FTD). Also, the mean classification precision (%) of each individual group and the corresponding 





Figure 11: confusion matrices showing the classification precision for each group in the four studies. Top left: HC vs EOAD. Top 
right: HC vs FTD. Bottom left: EOAD vs FTD. Bottom right: HC vs EOAD vs FTD. The values correspond to the rounded means 
across the 5 iterations. 
5.3.2. Significant brain regions 
As already mentioned, the first principal component was used to retrieve the linear combination of 
features accumulating the highest variance from the original dataset. In such linear combination, 
features with the higher weights correspond to the ones contributing more to the variance 
accumulated by that PC. In Figures 12 to 15, the weights given by PC1 to each brain region are 
represented in four boxplots, each one corresponding to a different classification study.  
 
Figure 12. Boxplot showing the weights given to every feature by the first principal component (PC1) in HC and EOAD study, the 
mean and standard deviations across the 5 cross-validation iterations are represented. The features are sorted from higher to lower 




Figure 13. Boxplot showing the weights given to every feature by the first principal component (PC1) in HC and FTD study, the 
mean and standard deviations across the 5 cross-validation iterations are represented. The features are sorted from higher to lower 
mean weights. In the x axis the names of the features are shown.  
 
Figure 14. Boxplot showing the weights given to every feature by the first principal component (PC1) in EOAD and FTD study, the 
mean and standard deviations across the 5 cross-validation iterations are represented. The features are sorted from higher to lower 




Figure 15. Boxplot showing the weights given to every feature by the first principal component (PC1) in HC, EOAD and FTD study, 
the mean and standard deviations across the 5  cross-validation iterations are represented. The features are sorted from higher to 
lower mean weights. In the x axis the names of the features are shown.  
In Figures 12 to 15, it can be noticed that most of the features were given negative weights and 
just a few of them, such as the ventricles size and volume or the choroid plexus were positively 
weighted. However, the sign of the weight given to a feature is just indicating the sign of its 
correlation with the principal component. That is, if an increase in a variable results in an increase 
of a PC and vice versa, it means that they are positively correlated and therefore the variable is 
positively weighted. And, on the contrary, a negative weight given to a variable means that it is 
negatively correlated with the PC. The larger a variable’s weight, the more that variable is 
contributing to that PC. 
The weights given to each variable were then plotted into a brain plot with the ggseg library from R 
studio. Since the sign of the weights is not relevant to the variable’s contribution to the PC 
accumulated variance, the weights were represented in absolute value. The resulting cerebral plots 
show the relevance of each brain region when differentiating between the classified groups. Two 
different plots were made for each classification study, one of them showing the subcortical 
volumes (Aseg atlas) and another one showing the cortical and subcortical thicknesses (Desikan-





Figure 16: Aseg atlases of the subcortical brain volumes painted according to the weights, in absolute value, given by the first 





Figure 17: Desikan-Killiany atlases of the cortical and subcortical thicknesses of the brain painted according to the weights, in 
absolute value, given by the first principal component of PCA in each study. 
5.4. Discussion of the results 
For each binary classification study, the probability of randomly predicting correctly a test subject 
was of 50%, whereas in the multiclass study that probability was of 33.3%. Thus, these last two 
values were taken as the accuracy baselines for the binary and multiclass studies, respectively. 
By looking at the mean accuracies in Table 5, it can be seen that the binary classification with better 
performance was the HC vs EOAD one, improving the baseline estimation in a 41.74%. The high 
accuracies here might be because the atrophy patterns between EOAD and HC patients are clearly 
distinguishable. Also, when comparing the HC and EOAD individual precisions in Figure 11, it was 
observed that both groups were equally identified, indicating that the percentage of subjects 
correctly identified as EOAD patients was similar to the one of HC. The same happened for the 
misclassification of both groups.  
In the classification between HC and FTD, the overall accuracy achieved was lower, meaning that 
the number of misclassified subjects was higher than in the previous study. This is probably due to 
the fact that the cerebral atrophy of FTD patients does not follow a pattern as specific as the one 
of EOAD, leading to greater difficulty in differentiating them from another group of patients. By 
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taking a closer look at the results, we observe that the number of subjects correctly classified as 
FTD was quite higher than the number of correctly classified HC. Thus, the probability of 
misclassifying a HC subject is higher than misclassifying a subject the other way around. However, 
both precisions exceeded 75%, which led to a reliable classification. 
On the other hand, the binary study between EOAD and FTD patients showed similar results to the 
one between HC and FTD, with an overall accuracy of 83%. In this case, the lower accuracy might 
be as well due to the more diffuse atrophy pattern of the FTD subjects. Again, the probability of 
misclassifying a EOAD patient into FTD is higher than in the opposite direction. However, the 
difference in the precisions between the EOAD and FTD groups is lower than in the HC vs FTD 
study due to higher variance in the data   . 
Regarding the proposed multiclass study between all three groups, it improved the performance 
with respect to the 33.33% baseline in a 44.39%, outperforming with respect to binary studies. Also, 
when looking at the individual precisions of each group, the FTD was once again the group with 
the lower number of misclassifications. The reason keeps being its less defined atrophy pattern, 
that leads to the algorithm to confuse atrophy patterns from other groups with the one of FTD. 
As can be seen in Figures from 12 to 15, the mean cortical thickness in the brain and the total gray 
volume were the two more weighted features of the dataset in all studies, meaning that were the 
ones contributing more to the PC1 variance. This proved that in both EOAD and FTD diseases 
there is an important gray matter loss with respect to healthy subjects. The fact that in the EOAD 
and FTD binary study these two features also accumulated variance might be because in FTD the 
amount of gray matter degeneration is not as much as in EOAD patients. 
By taking a look at the features contributing with more variance in the HC and EOAD patients 
(Figure 12), besides from the mean cortical thickness and the total gray volume, the specific regions 
showing more variance were the supramarginal, middle temporal and inferior parietal thicknesses. 
Also, a highly weighted feature was the supra tentorial volume, which is a feature that includes all 
the pial structures as well as the hippocampus and amygdala, among others. The EOAD pattern 
found highly correlates with the one found in [51] by Möller et al. 
When looking at Figure 13, it was observed that, compared to EOAD, FTD subjects also have a 
degeneration in nucleus accumbens, orbitofrontal areas and frontal insula in addition to a general 
cortical and subcortical loss of GM. This was also observed in Figure 14, where EOAD and FTD 
study results are shown. In this group differentiation, frontal insula plays an important role, which 
was also reported in the literature reviewed [52][53]. 
Moreover, Figure 15 shows the features contributing with more variance between the three groups. 
Once more, both the mean cortical thickness and the subcortical GM loss became the features 
accumulating more variance, followed by the middle temporal thickness and the total brain volume, 
which indicated a clear volume reduction in both neurodegenerative diseases with respect to 
controls.  
Finally, the general patterns of both diseases can be observed in Figures 16 and 17. From these 
plots, it was confirmed the more specific degenerative pattern of EOAD patients with respect to 
FTD. EOAD showed a more focused GM loss in temporal and posterior areas, while FTD subjects 
showed a more diffuse pattern, with weights more evenly distributed in the different regions. 
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6. EXECUTION SCHEDULE: GANTT DIAGRAM 
In order to develop the project in the expected time frame, from February 2021 to June 21th 2021, 
the different tasks to be carried out for the objectives accomplishment were listed and a specific 
time was assigned to each of them. In Figure 19, the Gantt diagram with the estimated times for 
each of the tasks is presented. 
The tasks to be performed in order to develop the project in the expected time frame were divided 
in six blocks: 
6.1. Planning. This block corresponds to the first two weeks of the project, since the first 
meeting with the tutor takes place in January 26 until the scope of the project is fully 
defined. 
6.1.1. Fix the objectives: the most important milestones to be fulfilled at the end of the 
project are defined. Checkpoint: list with the definitive objectives. 
6.1.2. Task’s definition: definition of the different tasks to be carried out in order to achieve 
the previously listed objectives. The realization of the Gantt chart is included in this 
sub-block. Checkpoint: list with the ordered tasks and definitive Gantt chart. 
6.2. Literature review. An in-depth research is conducted in different studies that have carried 
out ML approaches for the diagnosis of AD or FTD using MRI data or others such DTI 
data. This task is expected to last from February to mid-April. 
6.2.1. Literature review. The studies are searched and collected if they meet the inclusion 
criteria. This subtask lasts the same as the whole task 2 because of possible new 
publications. Checkpoint: table with the studies reviewed and their main 
characteristics. 
6.2.2. Evaluate feature selection methods. The feature selection methods and 
dimensionality reduction techniques used in the gathered papers are reviewed and 
the most appropriate technique for the project data is chosen. Checkpoint: feature 
selection/dimensionality reduction method chosen. 
6.2.3. Evaluate Machine Learning algorithm. Once with the feature selection methods 
evaluated, in mid-March, the same subtask must be performed for the ML 
classification algorithm. Checkpoint: ML classification algorithm chosen. 
6.2.4. Evaluate cross-validation method. The same review is done for the cross-validation 
method that aims to evaluate the algorithm performance. The subtask is expected to 
be finished by April 14. Checkpoint: cross-validation method chosen. 
6.3. Machine Learning model. The objective of this task, to be performed from mid-February 
for three months, is to code the ML pipeline. 
6.3.1. Model building. The first subtask is to build the model pipeline, with the feature 
selection, the ML algorithm and the cross-validation steps. Checkpoint: pipeline 
coded and implemented. 
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6.3.2. Model training and testing. Then, the model must be trained and tested with the 
available data and the chosen cross-validation method. Checkpoint: algorithm 
trained and tested with the cross-validation method chosen. 
6.3.3. Algorithm adjustment. Once the model was trained and tested, depending on the 
outcomes obtained the appropriate corrections and adjustments must be done. This 
subtask will close the ML model task approximately in mid-May. Checkpoint: 
readjusted pipeline. 
6.4. Results. With the algorithm already adjusted, it is time to present and analyse the results 
obtained. This aims to be done during the last three weeks of the project development, 
not considering the project delivery week. 
6.4.1. Present the results. The results must be analyzed and presented in the most 
appropriate way, with the help of tables and graphs that clarify them. Checkpoint: 
results understood and formally presented. 
6.4.2. Discussion of the results. With the results clearly presented, in mid-May, they must 
be discussed by performing an in-depth analysis. Checkpoint: section of the result’s 
discussion finished. 
6.4.3. Conclusion. Finally, while the results discussion is being done, conclusions must be 
extracted and expressed in the report. Checkpoint: conclusion section finished. 
6.5. Closeout. This stage closes the project development in the last week, from June 7 until 
June 21. 
6.5.1. Submission of the project. The project memory must be submitted on June 14. 






Figure 18: GANTT. Execution schedule by weeks of the project. On the left column the different tasks to be performed along the project execution (February 2021 – June 2021) are listed. The start and the due dates 





7. TECHNICAL FEASABILITY 
In this section, the SWOT analysis was developed. Both internal (strengths and weaknesses) and 
the external (opportunities and threads) factors affecting the current project were analysed. 
 
Figure 19: SWOT analysis of the project. Strengths, Weaknesses, Opportunities and Threads are listed. 
7.1 Strengths 
Firstly, the data used in this study was already pre-processed and labelled. Therefore, since all the 
features were already extracted from the MRI scans, the focus of the project could be placed on 
the ML classification and dimensionality reduction algorithms. 
Secondly, the classification pipeline implemented in Python was fully automated. It could perform 
a dimensionality reduction step of the data, plotting the brain regions providing more variance to 
the dataset, fitting the classification algorithm to the selected data, and to automatically cross-
validate the model and present its performance. At the end, the resulting pipeline provided 
reproducible results, which allows for applying the model to other datasets different than ours or 
being used in other centres. Moreover, it could be used with other neuroimaging modalities alone 
or combined with structural MRI. 
Finally, an unsupervised learning algorithm, PCA, was used to extract the most relevant brain 
regions and plot them in a brain atlas. This is a real advantage, since it provides a more clinical 
view of the problem, also allowing for tracking the disease evolution pattern in the future when new 
data of the patients is obtained. 
7.2 Weaknesses 
The first weakness this project encountered was the lack of data. It counted with a relatively small 
number of subjects, 161 (44 HC, 53 EOAD patients and 64 FTD patients), while to improve the 
results of the study more subjects should be included. Also, the data used belonged to a single 
neuroimaging modality, structural MRI, which also limited the algorithm performance. Therefore, 
better results would be expected if DTI or PET data had been available. 
Another weakness is the number of classification algorithms implemented, which was limited by 
the time available to carry out the project. Only SVM was assessed for the classification, while other 
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algorithms that proved promising results in the literature, such as Artificial Neural Networks or 
Regularised Extreme Machine Learning were not implemented. 
7.3 Opportunities 
The first opportunity is that ML was recently proposed as an alternative diagnostic tool for 
neurodegenerative diseases by means of neuroimaging data. It allows for better precision in 
diagnostics but also leads to explainable systems able to recognize patterns associated with 
healthy or pathological brain structures. All of this makes these techniques suitable for clinical 
applications and research.   
Also, although a wide range of studies and commercial softwares which aim to classify with the 
best accuracy as possible were developed, the algorithms were mostly treated as black boxes and 
little research was done in retrieving the most relevant features for the classification. In this aspect, 
the proposed study has an open opportunity. 
Finally, during the project development the 1st ISMRM Iberian Chapter Annual Meeting took place, 
and the current work, together with the doctoral student Agnès Pérez work, could be presented to 
the congress.  
 
7.4 Threads’ analysis 
Of course, in case the research project ended up giving rise to a start-up, an important thread would 
be enterprises such as qmenta that commercialize very powerful AI algorithms for the diagnosis of 
neurological diseases using neuroimage. Therefore, the market competition would be one of the 
obstacles for the project. 
However, the fact that nowadays machine learning techniques are shifting towards convolutional 
neural networks, that embed into a single algorithm both feature selection and classification 




8. ECONOMICAL FEASABILITY 
Although it is a publicly funded research thesis, in this section, the theoretical cost of the project 
based on the GANTT diagram is going to be described. To do so, the costs of human resources, 
the data used, software and hardware were divided in different packages with an associated cost. 
A summary table of the costs is presented in Table 6. 
Package Element of the package Element’s cost Package cost 
Human resources    
 Learning: 105 h 20 €/h  
 Development: 180 h 20 €/h  
 Close-out: 95 h 20 €/h  
   7.600 € 
Data    
 FreeSurfer segmentations 0 €  
 Demographic data 0 €  
   0 € 
Software    
 Python 0 €  
 R studio 0 €  
   0 € 
Hardware    
 Computer 800 €  
 Consumed electricity 21,98 €  
   821,98 € 
 
Total cost   8.421,98 € 
Table 6: table showing the theoretical cost of the project. The costs are divided in 4 packages: human resources, data, software 
and hardware. Each package is formed by different elements, which costs are presented. 
Firstly, regarding human resources, the salary of the student should be taken into account. The 
project development is designed to cover approximately 380 hours of work, which can be divided 
into a learning stage (105h), encompassing both planning and literature review; a development 
stage (180h), including the ML algorithm building and results tasks; and a close-out stage (95h) 
including the memory writing and the oral presentation of the project. Nonetheless, the salary of 
the student in the different stages is the same: 20€/h. Thus, the cost of this package amounts to 




Figure 20: hours dedicated to each stage of the project by the student:.47% to the development, 28% to the learning stage and 
25% to the close-out stage. 
Secondly, the images from which the data used in this project comes from were provided free of 
charge by the neurology service of Hospital Clinic. Moreover, the biomedicine department of the 
same hospital segmented the images with the FreeSurfer software. The resulting segmentations, 
as well as the corresponding demographic data, were also dispensed to the project free of charge. 
Thus, the overall cost of the data package is 0€. 
Thirdly, the software programs used in the development part were Python and R studio, both of 
them with completely free access, so the software package has no cost at all: 0€. 
Finally, an element to consider in the hardware package is the computer used, which is an HP 
pavilion of 2016 valued in approximately 800€. Also, the electricity consumption by the computer 
is considered. In all the hours of work the computer was used, and it consumes a mean of 400 W/h, 
so the electricity consumed for the project amounts to 152 kW. Taking into account that the price 
of electricity is around 0,14458 €/kW, the cost of electricity during the project was: 152 kW · 0,14458 
€/kW = 21,98 €. Thus, the total cost of the hardware package is 821,98€. 




9. NORMATIVE AND LEGAL ASPECTS  
This project is framed into the university, so it adheres to the University of Barcelona statute’s 
[Estatut de la Universitat de Barcelona - Universitat de Barcelona], specifically to “TÍTOL V”, 
chapters I, II and III. It states, among other remarkable points, that the research in University of 
Barcelona does not tolerate any project that does not aim to advance knowledge, improve life 
conditions, reduce social and economic inequalities and raise up innovation and business 
competitivity. 
Moreover, as stated in section 5, the project presented uses data retrieved from T1-weighted MRI 
scans of real patients. All the scans were acquired in the diagnostic imaging centre of Hospital 
Clinic, thus adhering to the bioethics committee of the hospital. Also, all the patients involved in the 
study must have provided their consent in written, and their demographic and clinical information 
is protected by the Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y 
garantía de los derechos digitales of the BOE. This normative includes a section, called 
“Disposición adicional decimoséptima. Tratamientos de datos de salud”, that states that the use of 
pseudonymised personal data for public health research is considered lawful as long as a technical 
separation exists between the research group and the group in charge of the pseudonymisation, 
so the real identifications remain unknown by the researchers. 
The current project fits into the Computer-Aided Detection/Diagnosis Software category, since it 
aims to process information retrieved from MRI images to generate a diagnosis support. Therefore, 
the proposed pipeline must be implemented in accordance to ISO 27799:2016 Health informatics 
– Information security management in health using ISO/IEC 27002. This International Standards, 
similarly to Ley Orgánica 3/2018, gives guidelines to appropriately preserve the confidentiality of 
personal health information that can be used in any project, whatever the form that information 
takes: numbers, words or, as in the present case, medical images. 
Finally, it cannot be omitted that the proposed algorithm aims to apply Artificial Intelligence to an 
actual medical diagnosis. However, although one would expect to find many regulations about it, 
there are currently no harmonized standards or laws that specifically regulate the use of Machine 
Learning or other forms of AI in the medical practice [54]. Nonetheless, Food and Drinks 
Administration (FDA) recently published a paper [55] where it describes a new potential approach 
to a regulation for AI and ML-driven software as medical devices. From this paper it can be derived 
that FDA would be enabled to evaluate and monitor a new software product from its premarket 




10.  CONCLUSIONS AND FUTURE LINES 
In conclusion, the presented project highlighted the importance of Artificial Intelligence algorithms 
for diagnostic imaging support. Specifically, the proposed algorithm showed the notable utility of 
machine learning automatic classification in the neuroimaging field, allowing to support the 
diagnosis of AD and other neurodegenerative diseases such as FTD. The main goals were 
achieved regarding both the algorithm performance and the retrieval of the atrophy patterns in both 
diseases. In addition, the algorithm proposed was accepted in the ISRMRM Iberian annual 
congress, which takes place on June 16 and 17.  
In light of the results obtained, we could affirm that EOAD’s patients present a more characteristic 
and less spread degenerative brain pattern than FTD patients, showing higher degeneration in 
temporal and posterior regions. This led to better classification performances when being classified 
versus control subjects. However, the algorithm improved the baseline performances (i.e., the ones 
obtained with a random classification of subjects) in more than a 30% in all the four studies, 
reaching a 44% of improvement in the multiclass classification between HC, EOAD and FTD 
controls, which is of great medical interest. 
It is relevant to mention that the pipeline proposed presented a clear advantage with respect to 
many of the classification algorithms reviewed. While in most studies the algorithms used were 
treated as black boxes, by performing an exhaustive analysis of PCA, the presented work was able 
to retrieve the brain regions that accumulated the highest variance of the dataset containing the 
subject groups to be classified. Since PCA is an unsupervised method, this milestone allows to 
study the neurodegenerative pattern of an unlabelled dataset where the different groups where a 
subject might belong are known, in this case HC, AD or FTD. Moreover, if data from the same 
subjects are collected throughout the disease, the brain signatures plotted become of strong 
interest for studying the neurodegenerative evolution of both AD and FTD diseases.  
Despite the accuracy of the presented pipeline reached optimal performance levels, it could be still 
improved. One way of doing so could be to feed the algorithm with a much larger dataset, leading 
to a better training and consequently to better results. Another interesting future implementation 
would be to both train and test the algorithm with other MRI modalities, such as DTI, so that other 
characteristic features, like white matter loss, were considered. Also, the current features could be 
fused with non-imaging data, as fluid biomarkers either from blood or CSF. Lastly, the proposed 
algorithm might be useful for the diagnosis of other neurodegenerative diseases such as Parkinson. 
Thus, future work could be made on the code in order to classify with higher accuracies between 
EOAD and FTD patients, and also to distinguish other diseases patients. 
To conclude, this project is another proof of concept of how medicine is moving towards a massive 
digitalization, improving speed and quality of healthcare. In this regard, biomedical engineering 
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12. ANEXES   
12.1. Python code: classification pipeline. 
 
1. #---------------------------- IMPORTS ---------------------- 
2. #----------------------------------------------------------- 
3. import pandas as pd  
4. import numpy as np 
5. import matplotlib.pyplot as plt 
6. from sklearn import metrics 
7. from sklearn import svm 
8. from sklearn.model_selection import GridSearchCV  
9. from sklearn.decomposition import PCA 
10. import seaborn as sns 
11. from scipy.stats import zscore 
12. import itertools 
13. from sklearn.model_selection import StratifiedKFold 
14. import warnings 
15. warnings.filterwarnings("ignore") 
16. import os 
17. #set working directory with the data tables available 
18. os.chdir(r"C:\Users\Laia.LAPTOP-1BS820LB\Desktop\4t\TFG\CODI") 
19.  
20. #---------------------------- FUNCIONS --------------------- 
21. #----------------------------------------------------------- 
22. def dic_pc(component,feature_weights,features): 
23.     ''' 
24.     Parameters 
25.     ---------- 
26.     component : int 
27.         number of components that want to be added 
28.     feature_weights : dictionary, with num of components as 
keys, another dictionary as value with features as keys and weights 
as values 
29.     features : list 
30.         feature's names list 
31.     Returns 
32.     ------- 
33.     mwf_pc : dictionary 
34.         name of features as keys and weight given to each 
feature as values.(sorted from higer to lower weights) 
35.     ''' 
36.     pc=feature_weights[component][0]   
37.     pc_abs=abs(np.array(pc))  
38.     sorted_pc=pc_abs  
39.     sorted_pc=sorted_pc.tolist() 
40.     sorted_pc.sort(reverse=True) 
41.     mwf_pc={} #more weighted features: dictionary with features 
as keys and weights as values 
42.     for i in range(0,len(sorted_pc)): 
43.         index=list(pc_abs).index(sorted_pc[i]) 
44.         mwf_pc[features[index]]=pc[index] 
45.     return mwf_pc 
46.  
47. #PLOT BAR OF X FEATURES MORE WEIGHTED 
48.  
49. def plot_bar(l,n,component_dic):  
50.     ''' 
51.  
52.     Parameters 
53.     ---------- 
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54.     l : int 
55.         starting index number, indicates which feature you want 
to start  
56.         plotting 
57.     n : int 
58.         stop index number, indicates which feature you want to 
stop plotting 
59.     component_dic : dictionary 
60.         dictionary with the features as keys and weights as 
vaules (sorted from higher to lower weights.) 
61.  
62.     Returns 
63.     ------- 
64.     None. 
65.  
66.     ''' 
67.     
blues=['steelblue','dodgerblue','deepskyblue','skyblue','lightskybl
ue', 
68.            'darkturquoise','paleturquoise'] 
69.     values=list(component_dic.values())[l:n] 
70.     tags=list(component_dic.keys())[l:n] 
71.     plt.bar(range(l,n),values,color=blues) #plotejo de la 1 a 
la n 
72.     plt.xticks(np.arange(l,n), 
tags,rotation='vertical',fontsize=14) 
73.     plt.yticks(fontsize=14) 
74.  
75.  
76. #PLOT CONFUSION MATRIX 
77. def plot_confusion_matrix(cm, classes, 
78.                           normalize=False, 
79.                           title='Confusion matrix', 
80.                           cmap=plt.cm.Blues): 
81.     """ 
82.     This function prints and plots the confusion matrix. 
83.     Normalization can be applied by setting `normalize=True`. 
84.     """ 
85.     if normalize: 
86.         cm=cm.astype("float") 
87.         cm = cm.astype('float') / cm.sum(axis=1)[:, np.newaxis] 
88.         print("Normalized confusion matrix") 
89.     else: 
90.         print('Confusion matrix, without normalization') 
91.         cm=np.round(cm,decimals=0) 
92.         cm=cm.astype(np.int64) 
93.     print(cm) 
94.  
95.     plt.imshow(cm, interpolation='nearest', cmap=cmap) 
96.     plt.title(title,fontsize=16) 
97.     plt.colorbar(shrink=1) 
98.     tick_marks = np.arange(len(classes)) 
99.     plt.xticks(tick_marks, classes, rotation=45,fontsize=14)  
100.     plt.yticks(tick_marks, classes,fontsize=14,rotation=45) 
101.  
102.     fmt = '.2f' if normalize else 'd' 
103.     thresh = cm.max() / 2. 
104.     for i, j in itertools.product(range(cm.shape[0]), 
range(cm.shape[1])): 
105.         plt.text(j, i, format(cm[i, j], fmt), 
106.                  horizontalalignment="center", 
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107.                  color="white" if cm[i, j] > thresh else 
"black",fontsize=14) 
108.  
109.     plt.tight_layout() 
110.     plt.ylabel('True label',fontsize=14,labelpad=5) 
111.     plt.xlabel('Predicted label',fontsize=14,labelpad=5) 
112.  
113. #--------------------------- ATLAS ------------------------- 
114. #-----------------------------------------------------------  
115.  






"rh_precuneus_thickness","rh_lateralorbitofrontal_thickness",        
"rh_medialorbitofrontal_thickness","rh_superiorfrontal_thickness", 
"rh_temporalpole_thickness","rh_precentral_thickness",        
"rh_entorhinal_thickness","rh_posteriorcingulate_thickness",        
"rh_parahippocampal_thickness","rh_parsopercularis_thickness",        
"rh_isthmuscingulate_thickness","rh_caudalmiddlefrontal_thickness",        
"rh_postcentral_thickness","rh_superiorparietal_thickness",        
"rh_rostralmiddlefrontal_thickness","rh_parsorbitalis_thickness",        
"rh_parstriangularis_thickness","rh_lateraloccipital_thickness",        
"rh_paracentral_thickness","rh_rostralanteriorcingulate_thickness",        
"rh_transversetemporal_thickness","rh_lingual_thickness", 




120. atlas_dk=["middle temporal","supramarginal","superior 
temporal","insula","inferior temporal","inferior 
parietal","fusiform","bankssts","precuneus","lateral 
orbitofrontal","medial orbitofrontal","superior frontal","temporal 
pole", "precentral","entorhinal","posterior cingulate", 
"parahippocampal","pars opercularis", "isthmus cingulate","caudal 
middle frontal", "postcentral", "superior parietal","rostral middle 
frontal","pars orbitalis","pars triangularis","lateral 
occipital","paracentral","rostral anterior cingulate", "transverse 
temporal", "lingual","cuneus", "frontal pole", 










126. #---------------- PARAMETERS (CHECK BEFORE RUN !!)--------- 
127. #----------------------------------------------------------- 
128.  
129. #PARAMETERS TO SELECT 
130. N_splits=5 # number of folds, 5-fold CV 
131. estudi='AD' #'AD'--> AD vs CTR, 'DFT'--> DFT vs CTR, "ADDFT"--> 
AD vs DFT 
132. m="yes" #If documents want to be saved, 'yes', else 'no' 





136. #--------------------------- DATA -------------------------- 
137. #----------------------------------------------------------- 
138.  
139. # We import cth (corticalsd) and volumes (subcorticals) data 
140. if estudi=='AD': 
141.     np.random.seed(10) #we place a seed to obtain reproducible 
results 
142.     Ngroup1=44 # number of subjects from the first group 
143.     Ngroup2=53  # number of subjects from the second group 
144.     N=Ngroup1+Ngroup2 # total number of subjects 
145.     df_rh=pd.read_csv("rh.tablecth.csv",sep='\t') 
146.     df_rh=df_rh.drop(columns=['rh.aparc.thickness'])  
147.     df_lh=pd.read_csv("lh.tablecth.csv",sep='\t') 
148.     df_lh=df_lh.drop(columns=['lh.aparc.thickness']) 
149.     df_subc=pd.read_csv("asegtable.csv",sep='\t') 
150.      
151. if estudi=='DFT': 
152.     np.random.seed(123) #we place a seed to obtain reproducible 
results 
153.     Ngroup1=44 # number of subjects from the first group 
154.     Ngroup2=64 # number of subjects from the second group 
155.     N=Ngroup1+Ngroup2 # total number of subjects 
156.     # AD + CTR 
157.     df_rh1 = pd.read_csv("rh.tablecth.csv",sep='\t') 
158.     df_rh1=df_rh1.drop(columns=['rh.aparc.thickness'])  
159.     df_lh1=pd.read_csv("lh.tablecth.csv",sep='\t') 
160.     df_lh1=df_lh1.drop(columns=['lh.aparc.thickness']) 
161.     df_subc1=pd.read_csv("asegtable.csv",sep='\t')  
162.         
163.     #Eliminate AD 
164.     df_rh1=df_rh1[:Ngroup1] 
165.     df_lh1=df_lh1[:Ngroup1] 
166.     df_subc1=df_subc1[:Ngroup1] 
167.      
168.     #DFT  
169.     df_rh2 = pd.read_csv("rh.tablecthDFT.csv",sep=';') 
170.     df_rh2=df_rh2.drop(columns=['rh.aparc.thickness'])  
171.     df_lh2=pd.read_csv("lh.tablecthDFT.csv",sep=';') 
172.     df_lh2=df_lh2.drop(columns=['lh.aparc.thickness']) 
173.     df_subc2=pd.read_csv("asegtableDFT.csv",sep=';')  
174.  
175.     # we concatenate the data 
176.     df_rh= pd.concat([df_rh1, df_rh2]) 
177.     df_lh= pd.concat([df_lh1, df_lh2]) 
178.     df_subc= pd.concat([df_subc1, df_subc2])     
179.     df_rh=df_rh.reset_index() 
180.     df_lh=df_lh.reset_index() 
181.     df_subc=df_subc.reset_index() 
182.     df_rh=df_rh.drop(['index'], axis=1)  
183.     df_lh=df_lh.drop(['index'], axis=1)  
184.     df_subc=df_subc.drop(['index'], axis=1)  
185.      
186. if estudi=='ADDFT': 
187.     np.random.seed(10) #we place a seed to obtain reproducible 
results 
188.     Ngroup1=53 # number of subjects from the first group 
189.     Ngroup2=64 # number of subjects from the second group 
190.     N=117 # total number of subjects 
191.     # AD + CTR 
192.     df_rh1 = pd.read_csv("rh.tablecth.csv",sep='\t') 
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193.     df_rh1=df_rh1.drop(columns=['rh.aparc.thickness'])  
194.     df_lh1=pd.read_csv("lh.tablecth.csv",sep='\t') 
195.     df_lh1=df_lh1.drop(columns=['lh.aparc.thickness']) 
196.     df_subc1=pd.read_csv("asegtable.csv",sep='\t') 
197.  
198.     df_rh1=df_rh1[44:44+Ngroup2] 
199.     df_lh1=df_lh1[44:44+Ngroup2] 
200.     df_subc1=df_subc1[44:44+Ngroup2] 
201.      
202.     df_rh1=df_rh1.reset_index() 
203.     df_lh1=df_lh1.reset_index() 
204.     df_subc1=df_subc1.reset_index() 
205.  
206.     df_rh1=df_rh1.drop(['index'], axis=1)  
207.     df_lh1=df_lh1.drop(['index'], axis=1) 
208.     df_subc1=df_subc1.drop(['index'], axis=1)  
209.      
210.     #DFT  
211.     df_rh2 = pd.read_csv("rh.tablecthDFT.csv",sep=';') 
212.     df_rh2=df_rh2.sort_values(["rh.aparc.thickness"], ascending 
= True) 
213.     df_rh2=df_rh2.drop(columns=['rh.aparc.thickness']) 
214.     df_lh2=pd.read_csv("lh.tablecthDFT.csv",sep=';') 
215.     df_lh2=df_lh2.sort_values(["lh.aparc.thickness"], ascending 
= True)  
216.     df_lh2=df_lh2.drop(columns=['lh.aparc.thickness']) 
217.     df_subc2=pd.read_csv("asegtableDFT.csv",sep=';')  
218.     df_subc2=df_subc2.sort_values(["Measure:volume"], ascending 
= True)  
219.      
220.     # we concatenate data 
221.     df_rh= pd.concat([df_rh1, df_rh2]) 
222.     df_lh= pd.concat([df_lh1, df_lh2]) 
223.     df_subc= pd.concat([df_subc1, df_subc2])     
224.     df_rh=df_rh.reset_index() 
225.     df_lh=df_lh.reset_index() 
226.     df_subc=df_subc.reset_index() 
227.     df_rh=df_rh.drop(['index'], axis=1)  
228.     df_lh=df_lh.drop(['index'], axis=1)  
229.     df_subc=df_subc.drop(['index'], axis=1) 
230.  





hypointensities', '4th-Ventricle','5th-Ventricle', 'CSF', 










235. #----- MEAN BETWEEN LEFT AND RIGHT CORTICAL MEASURES ------- 
236.      
237. features_r=(df_rh.columns).to_list()  
238. norm_r_l=pd.DataFrame(index=np.arange(N))  
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239. for i in range(0,35): 
240.     col_r=(df_rh.iloc[:,i]).to_numpy() 
241.     col_l=(df_lh.iloc[:,i]).to_numpy() 
242.     mean=(col_r+col_l)/2 
243.     norm=mean  
244.     name=features_r[i] 
245.     norm_r_l.insert(i,name,norm) 
246. norm_r_l.insert(35,'eTIV',df_rh.iloc[:,36])  
247.  
248. #------------- normalization + mean between left and right     
subcortical measures -------------------------- 
249.  
250. #normalization to intracranial volume 
251. features_subc=(df_subc.columns).to_list() 
252. for f in features_subc: 
253.     df_subc[f]=df_subc[f]/df_rh['eTIV'] 
254.  





























































302. df=pd.concat([df_subc, norm_r_l], axis=1) 
303. df=df.drop(['eTIV'], axis=1) #eliminem eTIV de les features 
304.  
305. # we add demographic data if the study is not EOAD vs HC 
306.  
307. if estudi=="DFT": 
308.     df_demo1=pd.read_csv("demo-neuropsico.csv",sep=';') 
309.     df_demo1.drop(df_demo1.columns.difference(["FS 
NEUROPSICO","Age","Gender"]),  
310.                   1, inplace=True) 
311.     df_demo1=df_demo1[:Ngroup1] 
312.     df_demo1=df_demo1.sort_values(["FS NEUROPSICO"], ascending 
= True)  
313.     df_demo1=df_demo1.drop(columns=["FS NEUROPSICO"]) 
314.      
315.     df_demo2=pd.read_csv("TransversalDFT.csv",sep=';') 
316.     
df_demo2.drop(df_demo2.columns.difference(["code","edadMRI","sexo"]
),  
317.                   1, inplace=True) 
318.     df_demo2["Age"]=df_demo2["edadMRI"] 
319.     df_demo2["Gender"]=df_demo2["sexo"] 
320.     df_demo2=df_demo2.drop(columns=["edadMRI","sexo"]) 
321.     df_demo2=df_demo2.sort_values(["code"], ascending = True) 
322.     df_demo2=df_demo2.drop(columns=["code"]) 
323.      
324.     df_demo=pd.concat([df_demo1,df_demo2],axis=0) 
325.     df_demo=df_demo.reset_index() 
326.     df_demo=df_demo.drop(['index'], axis=1) #eliminem index nou 
327.     df["Age"]=df_demo["Age"] 
328.     df["Gender"]=df_demo["Gender"] 
329.  
330. if estudi=="ADDFT": 
331.     df_demo1=pd.read_csv("demo-neuropsico.csv",sep=';') 
332.     df_demo1.drop(df_demo1.columns.difference(["FS 
NEUROPSICO","Age"]),  
333.                   1, inplace=True) 
334.     df_demo1=df_demo1[44:44+Ngroup2] 
335.     df_demo1=df_demo1.sort_values(["FS NEUROPSICO"], ascending 
= True) 
336.     df_demo1=df_demo1.drop(columns=["FS NEUROPSICO"]) 
337.      
338.     df_demo2=pd.read_csv("TransversalDFT.csv",sep=';') 
339.     
df_demo2.drop(df_demo2.columns.difference(["code","edadMRI"]), 1, 
340.                   inplace=True) 
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341.     df_demo2["Age"]=df_demo2["edadMRI"] 
342.     df_demo2=df_demo2.drop(columns=["edadMRI"]) 
343.     df_demo2=df_demo2.sort_values(["code"], ascending = True) 
344.     df_demo2=df_demo2.drop(columns=["code"]) 
345.      
346.     df_demo=pd.concat([df_demo1,df_demo2],axis=0) 
347.     df_demo=df_demo.reset_index() 
348.     df_demo=df_demo.drop(['index'], axis=1)  
349.     df["Age"]=df_demo["Age"] 
350.  




355. print(df.shape) # size of data 
356.  




361. for col in df_features: 
362.     if col!='Label':  
363.         df_norm[col]=zscore(df[col]) 
364.     else: 
365.         df_norm['Label']=df['Label'] 
366.          
367. df_norm.head() 
368.  




373. del features[-1]  
374. X = np.asarray(df_norm[features]) #DATA 





380. #PARAMETER SELECTION 
381. # we define the range of the C and gamma parameters (remember 
that gamma  
382. # is only used with rbf. 
383. svm_params = [{'C': [0.1,1, 10, 100,1000],  
384.               'gamma': [1, 0.1, 0.01, 0.001],  
385.               'kernel': ['rbf']}, 
386.              {'C': [0.1,1, 10, 100, 1000], 'kernel': 
['linear']}, 
387.              {'C': [0.1,1, 10, 100, 1000], 'kernel': ['poly']}]  
388.  
389. params={"SVM": svm_params} 
390.  
391. #-----------------------CUMULATIVE VARIANCE ---------------- 
392. #----------------------------------------------------------- 
393. if estudi=="AD": 
394.     tit='HC and AD' 
395.     png='expl_variance_AD.png' 
396. elif estudi=="DFT": 
397.     tit='HC and DFT' 




400.     tit='AD and DFT' 
401.     png='expl_variance_ADDFT.png' 
402.   
403. num_comp=len(features)-1 
404. pca = PCA(n_components=num_comp).fit(X) #we fit it with the 
train data,  
405.                                         #but apply into the 
whole data set 
406. expl_var=np.cumsum(pca.explained_variance_ratio_) 
407.  
408. idxs=np.where(expl_var>=0.80)[0] #minimum nº of components 
needed, where the  
409.                                 #cumulative expl.variance is 
80% or greater 
410. nc=idxs[0]+1  





415.          marker='X',markerfacecolor='steelblue', markersize=7) 
416. plt.title('Cumulative explained variance '+tit,fontsize=15) 
417. plt.xlabel('number of components',fontsize=15) 
418. plt.xticks(fontsize=14) 
419. plt.ylabel('cumulative explained variance',fontsize=15) 
420. plt.yticks(fontsize=14) 
421. plt.axvline(x=nc, color='k', linestyle='--',linewidth=1) 




425. #---------------------------- ML --------------------------- 
426. #----------------------------------------------------------- 
427.  
428. #EVALUATION (PERFORMANCE) 
429. accuracies_PCA={} #"name_model": {01:acc1, 02:acc2...}  
430.                     # where keys are the number of the 
iteration  
431.       
432. #CONFUSION MATRIX 
433. confusion_matrix={"TN":[],"FP":[],"FN":[],"TP":[]} #TP(true 
positive): well 
434. # predicted as patient; #FP: predicted as patient, truely 
control;  
435. #TN: well predicted as control; #FN: predicted as control, 
truely patient 
436.  










447. skf = StratifiedKFold(n_splits=N_splits) 
448. for train_idx,test_idx in skf.split(X,y): 
449.     X_train, X_test = X[train_idx],X[test_idx] 
450.     y_train, y_test = y[train_idx],y[test_idx] 
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451.     for name,model in models.items():   
452.         pca = PCA(n_components=nc) 
453.         X_tr = pca.fit_transform(X_train) #we fit it with the 
train data, but apply it into the whole data set 
454.         i=1 
455.         for component in pca.components_: #pca.components_: 
weights given to each feature in the order they 
456.                                           #appear in the 
dataset 
457.             if i in weights.keys(): 
458.                 weights[i].append(list(component)) 
459.             else: 
460.                 weights[i]=[] 
461.                 weights[i].append(component) 
462.             i+=1 
463.  
464.         X_tst= pca.transform(X_test) 
465.  
466.         for name,model in models.items():             
467.             #grid search of the best parameter combination 
468.             grid = GridSearchCV(model, params[name], refit = 
True,  
469.                                 verbose = 0,cv=10) 
470.             grid.fit(X_tr,y_train)   
471.             best_params.append(grid.best_params_) 
472.             clf=grid.best_estimator_ #classificator with the 
chosen parameters 
473.  
474.             #classification 
475.             clf.fit(X_tr,y_train) 
476.             y_pred=clf.predict(X_tst) #prediction 
477.  
478.  
479.             TN,FP,FN,TP=(0,0,0,0) 
480.             for idx in range(0,len(y_test)): 
481.                 if y_test[idx]==y_pred[idx]: 
482.                     if y_test[idx]==0: 
483.                         TN+=1 
484.                     else: 
485.                         TP+=1 
486.                 else: #si són diferents 
487.                     if y_test[idx]==0: 
488.                         FP+=1 
489.                     else: 
490.                         FN+=1 
491.  
492.             confusion_matrix["TN"].append(TN) 
493.             confusion_matrix["TP"].append(TP) 
494.             confusion_matrix["FP"].append(FP) 
495.             confusion_matrix["FN"].append(FN) 
496.  
497.             #Precsion 
498.             report=metrics.classification_report(y_test, 
y_pred, 
499.                                                  
output_dict=True) 
500.  
501.             reportg1=report['0'] 
502.             reportg1=reportg1['precision'] 




505.             reportg2=report['1'] 
506.             reportg2=reportg2['precision'] 
507.             reportgroup2.append(reportg2) 
508.  
509.  
510.             #Accuracy 
511.             accuracy=metrics.accuracy_score(y_test, y_pred) 
512.             if name in accuracies_PCA.keys():  
513.                 accuracies_PCA[name].append(accuracy) 
514.             else: 
515.                 accuracies_PCA[name]=[accuracy] 
516.  








525. for k in weights.keys(): 
526.     multiple_lists = weights[k] 
527.     arrays = [np.array(x) for x in multiple_lists] 
528.     mean_std_weights[k]=[[np.mean(k) for k in zip(*arrays)], 
529.                          [np.std(k) for k in zip(*arrays)]] 
530.      
531. ############## MEAN ACCURACY 
532. from statistics import mean, stdev 
533. ACmean=accuracies_PCA['SVM'] 
534. print( "MEAN ACCURACY:" , mean(ACmean)) 
535. print( "SD :" , stdev(ACmean)) 
536.  
537. ############## MEAN Precision 
538. print( "Group 1 precison:" , mean(reportgroup1)) 
539. print( "Group 1 precison std:" , stdev(reportgroup1)) 
540. print( "Group 2 precison:" , mean(reportgroup2)) 
541. print( "Group 2 precison std:" , stdev(reportgroup2)) 
542.  
543. #################### CONFUSION MATRIX ###################### 
544. CM=[] 
545. for k,value in confusion_matrix.items(): 
546.     CM.append(value) 
547. CM=(np.array(CM)).reshape(2,2) 
548. print(CM) 
549. # Plot non-normalized confusion matrix 
550. plt.figure(figsize=(6.5,6.5)) 
551. if estudi=="AD": 
552.     classes=['HC','EOAD'] 
553. elif estudi=="DFT": 
554.     classes=['HC','FTD'] 
555. else: 
556.     classes=['EOAD','FTD'] 
557. plt.figure(figsize=(6,6)) 
558. plot_confusion_matrix(CM, classes=classes, normalize= False,  
title='') 
559. plt.savefig("conf_matrix "+estudi) 
560.  
561.  
562. ################### DATA PCA weights 
563.  
564. if m=="yes": 
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565.       mwf_pc1=dic_pc(1,mean_std_weights,features) #weighted 
features pc1 
566.       #mwf_pc2=dic_pc(2,mean_std_weights) #idem pc2 
567.       #mwf_pc3=dic_pc(3,mean_std_weights) #idem pc3 
568.       #mwf_pc4=dic_pc(4,mean_std_weights) #idem pc4 
569.  
570.  
571. #We save the weights from the first component 




576. c1=0 #counter 
577. c2=0 
578. for key,val in my_dict.items(): 
579.     if key in features_aseg: 
580.         idx=features_aseg.index(key) 
581.         aseg_dic[c1]=[atlas_aseg[idx],val] 
582.         c1+=1 
583.     elif key in features_dk: 
584.         idx=features_dk.index(key) 
585.         dk_dic[c2]=[atlas_dk[idx],val] 
586.         c2+=1 
587.     else: 
588.         None 
589.  
590. if estudi=='AD': 
591.     PC_aseg_csv=pd.DataFrame.from_dict(aseg_dic,orient='index', 
592.                                        
columns=["region","weights"]) 
593.     PC_dk_csv=pd.DataFrame.from_dict(dk_dic,orient='index', 
594.                                      
columns=["region","weights"]) 
595.     PC_aseg_csv.to_csv("PC1_HCvsEOAD_aseg.csv")   
596.     PC_dk_csv.to_csv("PC1_HCvsEOAD_dk.csv")  
597.     title="HC - EOAD" 
598. if estudi=='DFT': 
599.     PC_aseg_csv=pd.DataFrame.from_dict(aseg_dic,orient='index', 
600.                                        
columns=["region","weights"]) 
601.     PC_dk_csv=pd.DataFrame.from_dict(dk_dic,orient='index', 
602.                                      
columns=["region","weights"]) 
603.     PC_aseg_csv.to_csv("PC1_HCvsDFT_aseg.csv")   
604.     PC_dk_csv.to_csv("PC1_HCvsDFT_dk.csv")  
605.     title="HC - FTD" 
606. if estudi=='ADDFT': 
607.     PC_aseg_csv=pd.DataFrame.from_dict(aseg_dic,orient='index', 
608.                                        
columns=["region","weights"]) 
609.     PC_dk_csv=pd.DataFrame.from_dict(dk_dic,orient='index', 
610.                                      
columns=["region","weights"]) 
611.     PC_aseg_csv.to_csv("PC1_ADvsDFT_aseg.csv")   
612.     PC_dk_csv.to_csv("PC1_ADvsDFT_dk.csv")  
613.     title="EOAD - FTD" 
614.  
615. old_names=["rh_middletemporal_thickness","rh_supramarginal_thic




"rh_fusiform_thickness","rh_bankssts_thickness",          
"rh_precuneus_thickness","rh_lateralorbitofrontal_thickness",        
"rh_medialorbitofrontal_thickness","rh_superiorfrontal_thickness",          
"rh_temporalpole_thickness","rh_precentral_thickness",          
"rh_entorhinal_thickness","rh_posteriorcingulate_thickness",          
"rh_parahippocampal_thickness","rh_parsopercularis_thickness",          
"rh_isthmuscingulate_thickness","rh_caudalmiddlefrontal_thickness",          
"rh_postcentral_thickness","rh_superiorparietal_thickness",          
"rh_rostralmiddlefrontal_thickness","rh_parsorbitalis_thickness",          
"rh_parstriangularis_thickness","rh_lateraloccipital_thickness",          







617. new_names=["middle temporal","supramarginal","superior 
temporal","insula","inferior temporal","inferior 
parietal","fusiform","bankssts","precuneus","lateral 
orbitofrontal","medial orbitofrontal",  "superior 
frontal","temporal pole","precentral","entorhinal","posterior 
cingulate","parahippocampal","pars opercularis","isthmus 
cingulate","caudal middle frontal","postcentral","superior 
parietal","rostral middle frontal","pars orbitalis","pars 
triangularis","lateral occipital","paracentral","rostral anterior 
cingulate","transverse temporal","lingual","cuneus","frontal 





620. for old,new in zip(old_names,new_names): 
621.     change_names[old]=new 
622. change_names["rh_MeanThickness_thickness"]="Mean thickness" 
623. change_names["Norm-Accumbens-area"]="Accumbens area" 
624. change_names["Norm-Inf-Lat-Ventr"]="Inferior Lateral Ventricle" 
625. change_names["Norm-choroid-plexus"]="Choroid Plexus" 
626.  
627. pc1_df=pd.DataFrame (weights[1], columns = features) 
628. pc1_df=pc1_df.reindex(abs(pc1_df.mean()).sort_values(ascending=
False).index, axis=1) 
629. pc1_df=pc1_df.rename(columns = change_names, inplace = False) 
630. plt.figure(figsize=(20,10)) 
631. plt.title(title,fontsize=22) 
632. ax = sns.boxplot(data=pc1_df) 
633. plt.ylabel("PC1 weights",fontsize=20) 
634. plt.xticks(rotation=90,fontsize=18) 
635. plt.yticks(fontsize=18) 
636. plt.show()    
637.      





















8.   data$X <- NULL 
9.   data<-subset(data,data$weights<0) 
10.   data$weights<-abs(data$weights) 
11.   return(ggseg(.data=data, atlas="aseg", 
mapping=aes(fill=weights))+ 
12.         
scale_fill_gradientn(colours=c("greenyellow","dodgerblue4","ligh
t blue","violet"),limits=c(0.0,0.2))+ 




17.   data$X <- NULL 
18.   data$weights<-abs(data$weights) 
19.   return(ggseg(.data=data, colour="white", 
mapping=aes(fill=weights))+ 
20.          
scale_fill_gradientn(colours=c("greenyellow","dodgerblue4","ligh
t blue","violet"),limits=c(0.0,0.2))+ 
21.          labs(title=title,cex=3)) 
22. } 
23.  
24. ## DATA i PLOTS 
25.  
26. #HC vs EOAD 
27.  
28. data_dk=read.csv("PC1_HCvsEOAD_dk.csv",header = TRUE) 
29. data_aseg=read.csv("PC1_HCvsEOAD_aseg.csv",header = TRUE) 
30.  
31. png("dk_CTRvsAD.png", width = 558, height = 389) 
32. aparcplot(data_dk,title="DK weights HC-EOAD") 
33. dev.off() 
34.  
35. png("aseg_CTRvsAD.png", width = 558, height = 389) 
36. asegplot(data_aseg,title='Aseg weights HC-EOAD')  
37. dev.off() 
38.  
39. # CTR vs EOAD vs DFT 
40.  
41. data_dk=read.csv("PC1_all_dk.csv",header = TRUE) 
42. data_aseg=read.csv("PC1_all_aseg.csv",header = TRUE) 
43.  
44. png("dk_all.png", width = 558, height = 389) 
45. aparcplot(data_dk,title="DK weights HC-EOAD-FTD") 
46. dev.off() 
47.  
48. png("aseg_all.png", width = 558, height = 389) 





52. # CTR vs DFT 
53. data_dk=read.csv("PC1_HCvsDFT_dk.csv",header = TRUE) 
54. data_aseg=read.csv("PC1_HCvsDFT_aseg.csv",header = TRUE) 
55.  
56. png("dk_CTRvsDFT.png", width = 558, height = 389) 
57. aparcplot(data_dk,title="DK weights HC-FTD") 
58. dev.off() 
59.  
60. png("aseg_CTRvsDFT.png", width = 558, height = 389) 
61. asegplot(data_aseg,title="Aseg weights HC-FTD")  
62. dev.off() 
63.  
64. # AD vs DFT 
65. data_dk=read.csv("PC1_ADvsDFT_dk.csv",header = TRUE) 
66. data_aseg=read.csv("PC1_ADvsDFT_aseg.csv",header = TRUE) 
67.  
68. png("dk_ADvsDFT.png", width = 558, height = 389) 
69. aparcplot(data_dk,title="DK weights EOAD-FTD") 
70. dev.off() 
71.  
72. png("aseg_ADvsDFT.png", width = 558, height = 389) 
73. asegplot(data_aseg,title="Aseg weights EOAD-FTD")  
74. dev.off() 
 
